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Abstract 
Cancer metastases are accountable for almost 90% of all human cancer-related deaths 
including breast cancer (BC). BC is the most common cancer among Canadian women, 
with one in four women diagnosed per year. BC is a heterogenous disease and is broadly 
classified into Luminal A (estrogen/progesterone receptor (ER/PR)+), Luminal B 
(ER/PR+ and human epidermal growth receptor 2+ (HER2+)), HER2+, and triple negative 
breast cancer (TNBC, ER-/PR-/HER2-). BC heterogeneity and progression are primarily 
dependent on intrinsic factors such as genetic or epigenetic changes to genes that regulate 
cell growth and proliferation. In addition, extrinsic factors such as, the extracellular 
matrix and adipocytes in the surrounding microenvironment contribute to cancer 
progression and initiation of metastasis. Therefore, the main aim of this thesis was to 
analyze the contribution of some of the intrinsic and extrinsic factors that regulate BC 
progression. One known intrinsic factor is CD24; a glycosylphosphatidylinositol-
anchored surface glycoprotein that can regulate proliferation and apoptosis of various cell 
types. Breast cancer stem cells (BCSCs), which can initiate tumor formation, maintain 
tumor heterogeneity, have high invasive properties, and favor metastasis, have low CD24 
expression. Moreover, drug treatment of TNBC tumors can cause a switch from CD24+ 
to CD24- and vice versa exhibiting differential drug resistance in these patients. In order 
to better understand the role of CD24, I first analyzed the CD24 gene, and found that the 
sequence of the mature peptide, but not the genomic structure is conserved over 200 
million years. Next, I studied the regulation of CD24 expression by the oncogenic Ras 
pathway and found that Ras is essential for suppression of CD24 surface expression. 
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Extrinsic factors, such as adipocytes, can also contribute to BC progression and 
metastasis. To study this, I developed a 3-dimensional co-culture system to mimic the in 
vivo interactions between BC cells and adipocytes. I found that adipocytes promote a 
mesenchymal-to-epithelial-like transition in BC cells suggesting that secondary tumour 
formation might be promoted by adipocytes. Overall, these data will aid in understanding 
the intrinsic and extrinsic factors that should be considered in the future development of 
combination drug treatments to successfully cure BC.   
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Chapter 1. Introduction 
1.1 Breast cancer and its subtypes 
Breast cancer (BC) is the most common cancer in women; with one in four cancer 
diagnoses being BC. According to Canadian cancer statistics 2017, in an average 
woman’s lifetime, one in nine women develop BC and one in 30 women die because of 
BC. Consequently, BC is the second leading cause of death from cancer in Canadian 
women. Five-year survival rates for BC diagnosed at early stages are 80-90%, falling to 
24% when diagnosed at more advanced stages. Advanced screening, diagnosis and 
research have decreased deaths from BC by 44% through the period of 1989 to 2014 [1, 
2]. 
BC is a heterogenous disease. Classification of BC into various types over the 
decades is based on histology, phenotype, and molecular profiling. 
Histologically, BC subtypes are characterized based on the location of tumor such 
as in ducts and lobes of the breast (Fig 1.1A). Moreover, these subtypes are broadly 
categorized into pre-invasive and invasive carcinomas based on their ability to invade the 
basement membrane. The growth of pre-invasive cancer is restricted to the ducts and 
lobes of breast tissue. Pre-invasive cancer is a benign condition but poses a risk of 
developing into invasive cancer. Pre-invasive cancers are sub-divided into ductal 
carcinoma in situ (DCIS) and lobular carcinoma in situ (LCIS). Heterogeneity in DCIS 
can lead to invasive cancer when untreated in comparison to LCIS. Invasive cancers have 
the ability to penetrate through the basement membrane. They are further classified as 
invasive ductal carcinoma (IDC) constituting 76% of BC and, invasive lobular carcinoma  
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Figure 1.1: Schematic representation of breast cancer subtypes: 
(A) Breast tissue consists of 10-20 lobes which are connected by ducts. Each lobe 
consists of lobules that secrete milk. Lobes and ducts are formed by luminal epithelial 
cells and surrounds the lumen which are further lined by basal/myoepithelial cells 
surrounded by basement membrane. The phenotype of the cell also designates the type of 
cancer as luminal or basal. (B) Pie chart showing the incidence of different types of 
histological invasive breast cancer subtypes. IDC: Invasive ductal carcinoma, ILC: 
Invasive lobular carcinoma. (C) BC subtypes are classified as Luminal A, Luminal B, 
HER2 positive and TNBC which are further classified as basal like (BL), 
immunomodulatory (IM), mesenchymal (M), luminal androgen receptor (LAR) based on 
molecular profiling. Receptor status that shows ER/PR are highly expressed in luminal A 
cancers compared to luminal B cancers. HER2 is expressed in both HER2 positive and 
Luminal B cancers. ER/PR or HER2 are absent in TNBC subtype. Chemotherapy is more 
effective in TNBC than any other subtype. Herceptin or trastuzumab targeted therapy is 
available for HER2 positive and Luminal B subtypes and endocrine therapy for ER/PR 
positive subtypes. Aggressiveness, prognosis and occurrence is indicated as BC%. 
Adapted from [3]. 
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(ILC) with a lower incidence constituting 7% of BC (Fig 1.1B). Other invasive BC 
include medullary, tubular, papillary, and mucinous carcinomas (Fig 1.1B) [4–8]. 
The anatomy of ducts and lobes within the breast consists of a lumen surrounded 
by luminal or epithelial cells followed by a layer of basal or myoepithelial cells which are 
intact with surrounding basement membrane (Fig 1.1A). Cancers originating from 
luminal or basal cell phenotype are defined as luminal or basal cancers. Molecular 
profiling of basal or luminal cancer cells can drive therapeutic decisions (Table 1.1). 
Molecular subtypes are broadly classified based on the expression of the estrogen 
receptor (ER), progesterone receptor (PR), human epidermal growth factor receptor 
(HER2 or c-erbB2), or the Ki67 proliferation marker. BC molecular subtypes are ER/PR 
positive cancers (luminal), HER2 positive cancers (basoluminal) and triple negative 
breast cancers (TNBC) (basal) [9, 10]. Luminal cancers constitute up to 70% of breast 
cancers and are further divided into Luminal A (40%) and Luminal B (30%) cancers. 
Luminal tumors have the lowest rate of recurrence and highest rate of disease-free 
survival with smaller tumors, and benefit from endocrine therapies [5, 11]. Luminal A 
cancers constitute only ER/PR-positive cancers whereas Luminal B cancers include both 
ER/PR-positive and HER2 overexpression. Patients with Luminal B cancer have worse 
disease prognosis than those with Luminal A cancers [12]. HER2-positive cancers occur 
in luminal or basal cell phenotypes and constitute 15% of breast cancers. Patients with 
HER2-positive tumors are generally younger than patients with ER/PR-positive tumors 
and benefit from targeted therapy with trastuzumab [10] (Fig 1.1C). TNBC are  
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Table 1.1 Breast cancer subtypes 
Breast 
cancer 
subtype 
Frequency of 
BC subtype 
ER/PR 
status 
HER2 
status 
Ki67 
status 
Therapy 
available 
Luminal A 25-30% + - - Hormonal 
treatment 
Lumina B 35-40% + +/- + Chemotherapy, 
anti- HER2 
and hormonal 
treatment 
HER2 
positive 
15% - +  Chemotherapy, 
and anti-HER2 
Basal - 
triple 
negative 
breast 
cancer 
10-15% - -  Chemotherapy 
Normal-
like 
10% + - - Chemotherapy 
+ overexpression, +/- moderate expression and –absence of the marker. 
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characterized by the presence of ER, PR or HER2 expression in less than 1% of the 
tumors and constitute about 15-20% of invasive breast cancers. However, the definition 
of negative has been debatable in the past, as it is considered ER/PR positive only when 
the expression is seen in >10% of the tumor [13]. TNBC tend to occur in younger women 
and has the poorest prognosis [13]. TNBC tumors tend to be larger, more aggressive, and 
more molecularly heterogeneous. TNBC tumors are characterized by high genetic 
instability, complex patterns of copy number alterations and structural rearrangements 
[14]. TNBC patients tend to have a high risk of metastasis and death within 5 years of 
diagnosis [15]. There are no targeted therapies available for TNBC treatment, and the 
treatment available is chemotherapy or radiotherapy (Fig 1.1C). TNBC patients respond 
to chemotherapy better than patients with other BC subtypes, but only 80% of patients 
show complete response [16]. 
1.2 Triple negative breast cancer 
TNBC show diversity in histologic patterns and subtypes which contributes to poor 
prognoses. In 2007 TNBC were defined as basal-like cancers and categorized into five 
subtypes using first generation gene sequencing [17]. Since then, refinement of TNBC 
subtypes has been constantly updated. Lehman et al. [18] performed gene expression 
analysis of 21 BC data sets and identified 6 BC subtypes, basal-like 1 (BL1), basal-like 2 
(BL2), immunomodulatory (IM), luminal/androgen receptor (LAR), mesenchymal (M), 
and mesenchymal stem-like (MSL). Furthermore, they refined 6 subtypes to 4 subtypes to 
reduce complexity of varying histology among tumor specimens [19]. Based upon these 
subtypes, several studies re-categorized TNBC  
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subtypes using different high throughput techniques such as genomics DNA copy number 
arrays, DNA methylation, exome sequencing, messenger RNA arrays, microRNA 
sequencing, and reverse phase protein arrays [13, 20–23]. However, here I will focus on 
the 5 subtypes, initially identified by Lehman et al. [18, 19], that include BL1, BL2, IM, 
LAR, and mesenchymal/mesenchymal stem-like (M) (Fig 1C).  
BL1 and BL2 TNBCs originate from basal/myoepithelial cells and constitute 75-
80% of TNBC. The remaining 25% of TNBC include a mixture of other BC subtypes, 
mostly HER2 positive which do not exhibit features like basal subtype. Histologically, 
BL1 is largely seen in ductal carcinomas and BL2 in medullary carcinomas. BL1 has an 
increased activation of DNA damage response and cell cycle pathways promoting cell 
proliferation while BL2 has an enriched growth factor signaling and basal/myoepithelial 
markers. (Table 1.2). Currently, chemotherapies such as anthracyclines, alkylating agents 
and taxanes are the only option for both early and advanced-TNBC, however, there are 
several targeted therapeutics based on the molecular classification in clinical studies 
indicating importance of molecular characterization of tumor and its treatment. For 
instance, phase II where 25-100 people are treated with new drug tested in phase I and 
phase III studies where several hundreds of patients are treated, targeting DNA damage 
response pathways with platinum salt and poly-ADP ribose polymerase 1 (PARP1) 
inhibitors respectively, showed significantly greater incidence of complete remission of 
pathology [24]. 
IM TNBC has increased expression of the genes related to T-cell, B-cell and 
natural killer cell function. Histologically, immune signaling pathways in the IM subtype   
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Table1.2: Molecular characteristics of TNBC subtypes.  
TNBC  
subtype 
Gene expression 
(Transcript level) 
Functions of the 
pathways 
Intrinsic 
subtype 
BL1 ↑ Ki67 ↑ Cell cycle division 
and regulation 
Basal, HER2 
BL2 ↑ EGFR, MET, EPHA2, 
TP63 and MME 
↑ Growth factor 
signaling, glycolysis 
and gluconeogenesis 
Basal 
IM ↑ NFkB, TNF and 
JAK/STAT 
↑ Immune cell processes Basal 
M ↑ TGFβ signaling genes and 
EMT- associated genes 
↑ Cell motility Basal, Normal-
like 
MSL ↓ Claudin 3, 4, and 7 
↑ TGFβ signaling genes and 
EMT-assoiated genes 
↑ Cell motility and 
cellular differentiation, 
growth pathways, 
angiogenesis, immune 
signaling, and stem cell 
associated genes. 
↓Proliferation and cell 
cycle regulation 
 
Basal, Normal-
like, Luminal B 
 
LAR ↑ Androgen receptor targets 
and co-activators 
 
↑Steroid synthesis and 
androgen/oestrogen 
metabolism 
 
Luminal A 
 
aAbbreviations: EGFR – epidermal growth factor receptor, EPHA2 - ephrin type A 
receptor 2, TP63 - tumor protein 63, MME - membrane metalloendopeptidases, NFkB – 
nuclear factor kappa B, TNF - tumor necrosis factor, JAK/STAT - janus kinase/signal 
transducers and activators of transcription, TGFβ - transforming growth factor β. 
Information in this table is sourced from [19, 21, 23]  
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overlap with signaling pathways found activated in medullary BC. The classification 
scheme of  Burstein et al. [23] combined basal-like with immunomodulatory pathways to 
identify basal-like immunosuppressed (BLIS) and basal-like immune activated (BLIA) 
subtypes. The BLIS subtype had a worse prognosis than the BLIA subtype. Despite its 
high-grade histology, the IM subtype is known to show better prognosis with the best 
overall and relapse-free survival rates in comparison to other TNBC subtypes. In a phase 
I trial, patients treated with immune checkpoint regulators such as PD-L1 showed an 
18.5% response rate. 
The LAR subtype falls under the 25% non-basal-like TNBC subtypes where in 
ER negative tumors, activation of hormone regulated pathways including 
estrogen/androgen metabolism is observed. Despite the classification as ER negative 
tumors, gene expression profiling of LAR shows molecular evidence of ER activation 
due to 1-2% of tumors expressing ER protein. . Histologically, LAR is reported to be 
lobular carcinomas.. LAR tumors also express androgen receptor (AR) targets and co-
activators. In a phase II trial, AR positive TNBC patients had a 12% complete response 
when AR was targeted with enzalumatide, indicating AR blockage as one therapeutic 
strategy for this subtype [25]. 
Mesenchymal and mesenchymal stem-like (MSL) subtypes are enriched with 
genes related to epithelial-to-mesenchymal transition (EMT) pathways. Specifically, 
MSL subtype show low levels of proliferation genes, which is accompanied by increase 
in gene expression associated with stem cells. Moreover, both M and MSL subtypes 
show a decrease in claudin 2, 3 and 7 which indicates EMT promotion. MSL also show 
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an upregulation of phosphatidylinositol-3-kinase (PI3K) signaling, contributing to cell 
proliferation. Histologically, this subtype is seen in metaplastic carcinomas. In addition, 
MSL are highly invasive and metastatic in nature in comparison to other subtypes and are  
chemoresistant. Therefore, blockage of PI3K pathway or the EMT pathway genes might 
be potential targets for this subtype (Table 1.2).  
1.3 Breast cancer metastasis 
Cancer metastases account for 90% of all human cancer-related deaths, including BC 
[26]. The metastatic cascade is a very complex and poorly understood process. It includes 
a series of steps that starts with tumor progression, tumor invasion, matrix remodelling, 
intravasation, extravasation, and ends with colonization of the tumor cells at distant sites 
(Fig 1.2). During metastasis, cancer cells undergo dissemination from the primary tumor 
and can achieve migration via an EMT, followed by a colonization of tumor at secondary 
site via mesenchymal to epithelial transition (MET) The most common secondary sites of 
metastasis in BC are bone, lung, liver, and brain, with bone and lung being especially 
common in TNBC [27]. The sites of BC metastasis can be categorized as non-visceral, 
which include bone, locoregional lymph nodes, brain, lungs, and visceral, defined as 
affecting organs in the viscera. The metastatic pattern among TNBC subtypes is different. 
For instance, TNBC patients with the LAR subtype display an increase in lymph node 
metastasis, and M subtype has higher tendency to metastasize in lungs in comparison to 
other subtypes.  
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Figure 1.2: Stages of BC initiation, progression and metastasis. 
Increased genetic and epigenetic instability leads to tumorigenesis and increase in cell 
proliferation (orange). Accumulation of mutations leads to heterogeneous tumor 
population including cancer stem cells (red), cancer cells with different mutation (dark 
purple) burden. Consequently, epithelial cells change to mesenchymal cells (green) to 
invade the basement membrane and remodel the extracellular matrix. Mesenchymal 
tumor cells intravasate into the circulatory system, migrate to distant sites. Extravasate 
into tissue parenchyma, colonize and form tumors at secondary sites such as lung or 
bone. Source for information [28]. 
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1.3.1 Epithelial to mesenchymal transition  
Genetic or epigenetic instability in BC cells at the primary site leads to increased 
proliferation and decreased apoptosis that enhance the tumor progression and 
accumulates tumor burden. Moreover, increased epigenetic or genetic alterations in BC 
cells allow them to undergo invasion, intravasation, survival and extravasation.EMT is a 
process whereby epithelial cells acquire mesenchymal cell-like properties with increased 
motility and decreased cell adhesion. This process has been divided as type I EMT, type 
II EMT and type III EMT. When re-arrangement or migration of cells occurs during 
embryonic development and organ formation, it is defined as type I EMT. If this change 
occurs during tissue regeneration or wound healing, it is defined as type II EMT. Here, I 
will discuss about type III EMT where acquisition of mesenchymal properties by 
epithelial tumor cells occurs  [29].  
1.3.1.1 Epithelial cells 
Normal epithelial cells are characterized by polarization of their plasma 
membrane with the presence of distinct surface domains that supports the structure, 
function and composition of the cells and interactions with the basement membrane and 
adjacent cells. The basement membrane is a specialized extracellular matrix (ECM) that 
separates the epithelial cells from connective tissue, keeps the epithelial cells together, 
and maintains the integrity of the tissue. The major components of basement membranes 
are laminins and type IV collagen. The composition of basement membrane varies across 
the tissues based on the physiologic or pathophysiologic state of tissue. The permeability, 
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cell-cell adhesion strength, cell-microenvironment interaction, and transportation of some 
metabolites is regulated by the cell type junctions including adherens junctions, tight 
junctions, gap junctions, desmosomes, and hemidesmosomes. [16, 26, 30–39]. Adherens 
junctions, and desmosomes are cadherin-containing anchoring junctions that bind to 
adjacent cells giving strength and rigidity to the epithelia.  
Among the classical cadherins, E-cadherin is the most widely expressed in 
epithelial cells and considered an important marker for the epithelial phenotype [40, 41]. 
E-cadherin plays an essential role in cell-cell interactions and in epithelial integrity of the 
cell. The tight junction proteins occludins and claudins stop diffusion of proteins and 
some lipids in the plasma membrane. Moreover, tight junctions have a role in cell-cell 
interactions and epithelial cell polarity. Hemidesmosomes are integrin-containing 
junctions and gap junctions are connexon-containing junctions that participate in cell-cell 
and cell-matrix adhesions, respectively. Epithelial cells undergo trans-differentiation, a 
natural process of cells, where they transform into a different cell type in order to migrate 
during wound healing, tissue generation, or metastasis. When the trans-differentiation is 
triggered in epithelial cells to transform into mesenchymal cells, epithelial cells acquire 
mesenchymal properties such as increased expression of vimentin, N-cadherin, 
fibronectin, smooth muscle actin and matrix metalloproteinases (MMPs) (Fig 1.3). 
1.3.1.2 Invasion 
Genetic or epigenetic instability within a tumor cell, accompanied by external 
inflammatory tumor-associated stroma, induces EMT. Particularly, initiation of EMT is   
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Figure 1.3: Epithelial to mesenchymal transition and mesenchymal to epithelial 
transition: 
Transition of stable, polar epithelial cancer cells (orange) to migratory, non-polar 
mesenchymal cancer cells (green) is known as EMT. Illustration shows the changes in the 
biomarkers where epithelial markers (E-cadherin, ZO-1, claudin-7) are suppressed during 
mesenchymal status and regain their expression during MET. In contrast, mesenchymal 
biomarkers (vimentin, N-cadherin and fibronectin) are suppressed during epithelial status 
and expressed during mesenchymal status. Activation of TGFβ signaling, 
wingless/integrated (Wnt) signaling by external factors enhance mesenchymal phenotype, 
however activation of MET is still elusive. Cancer stem cells (CSCs) shown in red are 
increased during EMT and decreased during MET. Other colours such as dark purple in 
tumor represent the heterogenous tumor population. 
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regulated by intrinsic factors such as activation of signaling pathways, transcription 
factors, microRNAs, or epigenetic modulation influenced by extrinsic factors such as 
tumor-stroma interactions [42]. Stromal cells such as adipocytes can induce the 
expression of mesenchymal markers and promote invasiveness of BC cells, suggesting a 
pro-EMT regulation [43]. Also, adipocytes from visceral white adipose tissue (WAT) 
have enhanced effects on the EMT of BC cells compared to those from subcutaneous 
WAT [44]. The stromal secretions such as growth factors, including transforming growth 
factor (TGFβ), epidermal growth factor (EGF), platelet-derived growth factor (PDGF) 
and hepatocyte growth factor (HGF), can also induce EMT as well as inducing other 
functions of cancer cells such as proliferation, protection from apoptosis, and 
angiogenesis [45, 46]. The signaling pathways that are associated with induction of EMT 
are the TGFβ, wingless/integrated (Wnt)/β-catenin, and Notch pathways [42]. These 
pathways activate the master regulators of EMT: the EMT-transcription factors (EMT-
TFs) Snail, Slug, zinc finger E-box binding homebox 1 (ZEB 1), ZEB2, goosecoid, 
forkhead box C1 (FOXC1), FOXC2 and twist family basic helix loop helix (bHLH) 
transcription factor (TWIST). EMT-TFs transcriptionally downregulate the expression of 
adherens junction and integrin proteins, which allows transformed cells to lose polarity 
and dissociate from adjacent cells and the basal membrane [37, 47]. The E-cadherin 
promoter is repressed by Snail, Slug and ZEB2 directly and by TWIST1, FOXC2, and 
ZEB1 indirectly, which disrupts cell polarity and maintains the mesenchymal phenotype 
to promote EMT [47, 48]. TWIST1 can transform normal mammary epithelial cell into 
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mesenchymal like cells that have increased expression of vimentin, N-cadherin and 
fibronectin [49] (Fig 1.3).  
Once EMT is initiated, cells lose polarity and become mobile whereupon they can 
invade the basement membrane and degrade the extracellular matrix. Snail1 and Snail2 
expression in BC cells increase membrane type1-matrix metalloproteinase (MT1-MMP), 
MT2-MMP, MT4-MMP and MMP2 expression which further leads to the degradation 
ofbasement membrane and allows subsequent tumor metastasis [50]. EMT-TFs induce 
the formation of specialized structures called invadopodia, that invade local ECM. 
TWIST1 and TGFβ enhance invadopodia formation, which actively promotes 
degradation of the matrix [51].Moreover, MMPs and other chemokines released from 
epithelial cells and inflammatory cells disrupt the basement membrane and promote focal 
degradation of extracellular matrix proteins such as collagen and laminins [29]. 
1.3.1.3 Intravasation 
 Cancer cells undergo intravasation to invade into the lymphatic and blood 
circulatory systems. EMT markers, matrix remodeling proteins and angiogenic factors 
have an essential role in intravasation of cancer cells. In pancreatic cancer, increases in 
ZEB1 expression enhances the migration through the endothelial barrier followed by 
metastatic colonization [52]. Activation of membrane bound proteins, MT1-MMP and 
MT2-MMP but not MMP, allow cancer cells to come in contact with endothelial cells 
and then intravasate into the vasculature [50]. To disrupt the vascular integrity during 
both intravasation and extravasation, cancer cells express vascular endothelial growth 
factor (VEGF), MMPs, and a disintegrin and metalloproteinase (ADAM) [53]. 
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Once the cancer cells disseminate, they intravasate into the circulatory system as 
single cells or clusters in a mesenchymal state. Circulating tumor cells (CTCs) retain 
mesenchymal properties via activation of the TGFβ pathway [54]. Moreover, in a mouse 
mammary tumor model, increases in the protein expression of the EMT marker TWIST1 
was found during early stages of tumor formation, and cells remain in a mesenchymal 
state until they reach the bone marrow [55]. 
1.3.1.4 Survival and extravasation 
The circulatory system provides a hostile situation for CTCs, with constant 
clearance by natural killer (NK) cells and physical strain from the circulation [56]. CTCs 
survive the immune insult followed by the attachment to the wall of blood vessel to 
finally prepare for extravasation from the circulation. CTCs, once in circulation, rapidly 
interact with platelets via tissue factor present on cancer cells. Platelets provide physical 
protection by coating the CTCs and also by inhibiting lysis by blocking NK cells via 
TGFβ and PDGF [56]. Removal of TGFβ in platelets impairs the extravasation of CTCs 
and thus reduces metastasis [57]. In addition, platelets can change intracellular signaling 
within cancer cells to contribute to successful metastasis [57]. Moreover, neutrophils in 
circulation can also provide physical protection to CTCs from NK cells and further aid in 
extravasation [56]. Expression of TWIST1 or Snail1 in mammary epithelial cells 
promotes survival by triggering microtenacle formation, a microtubule based membrane 
protrusion that allows attachment of CTCs to leukocytes, platelets and endothelium to aid 
in extravasation [51]. Furthermore, β1 integrin signaling not only maintains EMT 
phenotype but also triggers protrusion formation in CTCs that mediate extravasation [58]. 
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Macrophages at the site of CTC attachment also play a role in invadopodia formation, 
disruption of endothelium, and extravasation. Cancer cells that metastasize to the lung 
show high expression of VEGF that facilitates disruption of the endothelium. Increase in 
MMPs such as MMP2, MMP1 and cyclooxygenase-2 (COX2) also promote 
extravasation and metastasis [53, 59]. Collectively, all the factors discussed above work 
together to aid and contribute in survival and extravasation of CTCs. 
1.3.2 Mesenchymal to epithelial transition  
 The reverse process of EMT is known as MET, where the mesenchymal CTCs 
survive the circulation, extravasate into the distant tissue parenchyma and dedifferentiate 
into an epithelial phenotype to form a secondary tumor (Fig 1.2). The mechanisms 
involved in organ specific extravasation of CTCs are still elusive. According to previous 
studies, many factors such as the circulatory system, microenvironment, adaptability to 
the tissue parenchyma, and tumor initiating ability have an impact on colonization of 
CTC’s at a specific site. In some cancers, like colorectal cancer, metastasis in the liver is 
explained by the draining of blood in the portal vein into the liver from the colon [60]. 
When CTCs enter the microenvironment of the tissue parenchyma at a secondary site, 
they encounter ECM and stromal cells including fibroblasts, adipocytes, and 
inflammatory cells. In prostate and breast cancer, E-cadherin is re-expressed or 
upregulated when co-cultured with hepatocytes, which indicates MET of cancer cells at a 
secondary site [61, 62]. Aokage et al. showed that non-small cell lung cancer cells 
(NSCLC) express low E-cadherin while migrating through lymphatic vessels. Moreover, 
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when NSCLC encounter lung parenchyma, they re-express E-cadherin, to undergo 
micrometastasis [63]. Co-culture of adipose tissue-derived stem cells upregulates E-
cadherin expression, and downregulates vimentin and N-cadherin expression in liver 
cancer cells [64]. However, how these factors are involved in macro- or micro-metastases 
induction is unclear.  
During EMT, cell division is repressed by Snail1 and ZEB2 via inhibition of 
cyclin D activity, which slows down the cell proliferation and promotes differentiation 
[51]. Regaining epithelial properties is essential for cancer cells to proliferate and 
colonize at distant organs [65]. Several pathways such as the Ras- extracellular signal 
regulated kinases (ERK), PI3K-Akt, and Wnt signaling pathways in BC cells induce an 
epithelial phenotype [60, 66]. TFs such as Snail and TWIST that promote EMT are also 
repressed during metastasis which further assists in suppressing the mesenchymal 
phenotype. In various studies, it was proven that mesenchymal cells acquire epithelial 
properties after metastasis which was recognized by expression of E-cadherin [60, 62, 
67]. Forced expression of E-cadherin can, in fact, induce MET in prostate cancer cells 
[68]. Moreover, cancer cells use E-cadherin to connect with local normal epithelial cells 
and establish the tumor formation at a secondary site. However, mechanisms involved in 
colonization of secondary tumors (MET) are not well studied in comparison to EMT that 
occurs at the initiation of metastasis.  
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1.3.3 Self renewal: breast cancer stem cells 
The self-renewing ability of cancer cells is an important trait to reconstitute other 
subpopulations and maintain tumor heterogeneity. This property belongs to a 
subpopulation within tumors called CSCs. In breast tumors, these cells are known as 
breast cancer stem cells (BCSCs) [69]. There are some similarities between normal stem 
cells and CSCs in terms of gene expression but CSCs are not always generated from 
normal stem cells [70, 71]. Notch, hedgehog (Hh), and Wnt pathways are essential for 
maintaining normal tissue processes. However, dysregulation in these pathways can lead 
to transformation of normal stem cells into CSCs. In addition, CSCs can be generated 
from mutated cancer cells that acquire stem-like properties. BCSCs can be identified by 
their high expression of CD44, low expression of CD24, and high aldehyde 
dehydrogenase (ALDH) activity (CD44+CD24-ALDH+) [69, 72]. Moreover, the 
combination of a high CD44/CD24 ratio and ALDH+ on BCSCs is conserved during 
metastasis, from primary tumor to CTCs and the distant metastasis [73]. When 
transplanted into immunocompromised mice, BCSCs have the ability to self-renew and 
reconstitute other subpopulations and recapitulating the original heterogenous tumor [74, 
75]. Metastatic cells with stem cell-like properties isolated from patient-derived xenograft 
models of BC have a tumor initiating capacity, leading to the formation of large tumors 
[76]. BCSCs are highly associated with increased invasiveness, tumor progression, and 
metastasis [77, 78]. BCSCs are known to be radiation and chemotherapy resistant [79–
81]. Tumors with a high percentage of BCSCs generally have a worse prognosis [82] 
since as few as 1 × 103 BCSCs can regenerate an entire tumor, including both CD24− and 
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CD24+ cells [83]. Moreover, BCSCs are considered an independent prognostic factor for 
poor prognosis in TNBC [84]. 
EMT is associated with the formation of CSCs and the presence of CSCs promote 
EMT [77]. Induction of EMT markers such as TGFβ, TWIST and Snail can induce 
normal mammary cells to transform into CSCs [85]. In addition, TGFβ1 increases the 
BCSC population and promotes local tumor invasion and metastasis [86]. Consequently, 
EMT induced CSCs increase mammosphere formation where cells start to clump 
together. However, the promotion of CSC formation by EMT is also dependent on cell 
type during tumor progression [87].  
CSCs isolated from the mammary gland or BC exhibit EMT properties [49, 88]. 
Specifically, E-cadherin mRNA is downregulated and mesenchymal vimentin, N-
cadherin, and fibronectin mRNA are upregulated in CD44+CD24- cells [49]. In addition, 
EMT-TF such as TWIST1, Snail 1, ZEB1, ZEB2, goosecoid, FOXC2, Y-box binding 
protein 1 (YB-1), ladybird homebox 1 (LBX-1), Six1 and hypoxia inducible factor (HIF) 
maintain the stemness of CSCs [89]. Similarly, microRNA miR200 maintains the stem 
cell state [90, 91]. Overall, EMT and CSCs together lead to formation of large tumors 
with the ability to invade, and survive therapy with a high chance of recurrence, which 
are a deadly combination for patients. In addition, CSCs migrate to the distant organs 
along with CTCs and contribute towards the initiation of tumor and metastases formation, 
where CSCs not only initiate the metastasis but also maintain the heterogeneity of the 
secondary tumor [92]. 
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1.4 Obesity and its effect on breast cancer progression 
Obesity is defined as an unequal distribution of body weight for height with high 
accumulation of adipose tissue that leads to mild, chronic, and systemic inflammation. 
According to the World Health Organization (WHO) standards, body mass index (BMI) 
≥ 25 kg/m2 is overweight and BMI of ≥ 30 kg/m2 is obese. Over 2 billion people in the 
world are overweight or obese and it is estimated that by 2030 >3.3 billion (57.8%) of the 
adult world population will be overweight or obese [93, 94]. Obesity is now considered 
as one of the most important risk factors contributing to overall disease burden in the 
world [95]. Common health consequences of patients that are overweight or obese 
include cardiovascular diseases, diabetes, osteoarthritis, and some cancers including 
endometrial, ovarian, breast, prostate, liver, gall bladder, kidney, and colon [96, 97].  
Over 40% of cancer patients are classified as overweight or obese [98, 99]. Obese 
women with BC have larger tumors and enhanced metastasis that contributes to a 30% 
increased risk of death [100–102]. Obesity is one of the various factors that influences 
BC progression in both pre-menopausal and post-menopausal women [103]. Obese post-
menopausal women are at high risk for ER/PR positive BC whereas obese pre-
menopausal women are at higher risk of developing TNBC compared to lean women 
[104]. Moreover, obese patients do not respond to therapy as well as lean patients, 
particularly when diagnosed with TNBC, also contributing to the overall worse prognosis 
[103, 104]. 
24 
 
Body fat distribution plays an important role in disease progression. Adipose tissue 
(AT) is divided into two types: brown adipose tissue (BAT) and white adipose tissue 
(WAT). BAT depots are present in newborn babies and help maintain body temperature 
by thermogenesis. In infants, BAT is located in interscapular and perirenal regions where 
BAT in the interscapular region gradually decreases with age [105]. WAT not only stores 
energy but is also an endocrine organ that produces metabolites, hormones, and cytokines 
(adipokines). WAT depots are classified into visceral AT (VAT) and subcutaneous AT 
(SAT). WAT contained in the intra-abdominal, thoracic, and pelvic cavity surrounding 
the omentum, gut, kidney, heart and gonads is VAT. WAT depots beneath skin are SAT. 
SAT is widely distributed and divided into upper and lower SAT. Lower SAT is mainly 
located in the leg and hip regions where as upper SAT is located in face, arms, abdomen, 
and breast. Breast tissue is composed of 90%  WAT is the only SAT with permanent 
interactions with epithelial cells and is involved in normal mammary gland development 
[106]. In addition, adipocytes constitute about 70% of bone marrow volume [107]. The 
number of adipocytes in bone marrow increase with both age and obesity [108].  
WAT depots have different effects on the advancement of diseases such as 
metabolic syndrome or cancer based on the location. In comparison to SAT, VAT is more 
metabolically active, with accumulated inflammatory cells and cytokines [109]. Together, 
these contribute to cancer, including BC, and insulin resistance leading to several 
diseases such as metabolic syndrome and diabetes. Women with visceral obesity have a 
higher risk of BC occurrence than women with subcutaneous obesity [110]. Both obesity 
and TNBC are associated with visceral metastases development [27, 111]. In obese 
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patients with ovarian or prostate cancer, an increase in the number of bone marrow 
adipocytes is correlated to increased skeletal metastasis [112, 113]. The role of bone 
marrow adipocytes in metastasis of BC to bone has not yet been examined.  
Obesity is characterized by the enlargement of WAT depots with excess 
engorgement of lipids in adipocytes. The increase in engorged adipocytes induces 
systemic changes such as increases in adipokines, secretion of inflammatory cytokines, 
lipid metabolites, fibrosis, and CSC, that can contribute to BC progression [114] (for 
details refer to 1.6.6, and 1.6.7). In obese BC patients, the increase in adipocyte size 
causes a stiffer ECM to be deposited by adipocyte stromal cells [115] (Fig 1.4). Chronic 
inflammation from obesity leads to secretion of cytokines such as interleukin-6 (IL-6) 
and tumor necrosis factor-α (TNF-α) that are known to affect cancer progression (for 
details refer to 1.6.6). When they occur together, obesity and TNBC are the worst 
combination for a patient’s outcome, as obesity reduces the therapeutic response even 
further.  
1.5 Tumor microenvironment and its effect on cancer progression 
Genetic or epigenetic instability in cancer cells leads to activation of signaling 
networks, which interacts with neighbouring cells and ECM generating a tumor 
microenvironment (TME) convenient for tumor growth. The TME is one of the important 
extrinsic factors that contributes to the progression of BC. The TME is comprised of 
ECM proteins and several stromal cell types such as endothelial cells, fibroblasts, 
immune cells, adipocytes, and inflammatory cells that play a crucial role in tumor growth  
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Figure 1.4: Schematic illustration of adipose tissue under normal and obese 
conditions: 
Obesity induces both local and systemic changes where there is an increase in lipid 
content with in the cells, and macrophages that leads to accumulation of pro-
inflammatory cytokines and adipokines such as leptin, and hepatocyte growth factor 
(HGF). Adipocytes under obese conditions accumulate collagen that leads to stiffening of 
the microenvironment. ECM shown in green, under obese conditions ECM is increased. 
Image was adapted from [131].  
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and development [116]. Abnormal conditions, like those seen in obesity, can contribute 
to BC progression by changing the TME [114].  
In the normal breast, luminal and basal epithelium are surrounded by the 
basement membrane that constitutes of laminin-rich, collagen type IV, and proteoglycan 
based ECM. In vitro, mammary cells form acinar structures with a lumen and can 
functionally differentiate and produce milk proteins in in vitro 3 dimensional (3D) 
cultures but not 2D cultures, highlighting the importance of ECM in mammary 
development [117]. Laminins in the basement membrane maintain the polarity of 
epithelial cells [118]. In addition to structural support, the ECM involves in biochemical 
and mechanical cues that regulate cell behaviour. Viscous and elastic properties of ECM 
surrounding the cell contributes to the cell fate [119]. During tumor progression, an 
increase in ECM remodelling enzymes  such as MMP 1, 2 and 9, and cathepsins by 
stromal cells degrade laminins and other ECM proteins changing the elasticity of ECM 
that  contribute to contractility and motility of cells in EMT [50, 120–122]. In addition, 
there is an upregulation of fibrillar collagens I, III and V, matricellular proteins, 
glycosaminoglycans, and fibronectin that increase fibre crosslinking and induce a shift 
from the laminin rich normal breast tissue to a collagen rich tumor microenvironment. 
This increase in collagen leads to an increase in ECM stiffness [123, 124]. An increase in 
lysyl oxidase by BC cells, a copper-dependent amine oxidase that initiates the process of 
the intra and inter crosslinking of collagen strands leading to increase in ECM stiffness, 
also contributes to invasiveness of BC progression [125, 126]. ECM stiffness in turn 
promotes BC progression, increases pro-inflammatory cytokine secretion, and decreases 
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adipocyte lipolysis [127–129]. ECM stiffness leads to an upregulation of ERK signaling 
thereby leading to increases in BC cell proliferation. The increased ratio of stiffer ECM 
to adipocyte size in the mammary gland can also enhance cancer progression [115]. 
Stromal cells in the TME secrete several secretory factors such as cytokines, chemokines, 
growth factors and extracellular vesicles, and interact with tumor cells to contribute to 
breast cancer progression and invasion. Tumor-associated macrophages (TAM) promote 
angiogenesis and invasion by upregulating VEGF. In addition, TAM’s secrete tumor 
promoting factors such as ECM-remodelling enzymes, growth factors, and inflammatory 
cytokines that contribute to tumor progression [130]. Fibroblasts when co-cultured with 
breast cancer cells, produce growth factors such as hepatocyte growth factor that promote 
tumor growth [132]. Moreover, adipocytes which are major component of the breast have 
both mechanical and biochemical interactions with BC cells that are involved in tumor 
progression (refer to section 1.7.4) [133].  
1.6 Model systems: 2D and 3D culture systems 
Cells in 2D cell culture lack the 3D organization of cells between each other or 
with the ECM as observed in organs and tissues in vivo [134]. In vitro 3D cell culture 
methods were thus developed to better mimic in vivo conditions and bridge the gap 
between in vitro and in vivo experiments [135–137]. Unlike cells in 2D cultures, cells 
grown in 3D obtain a more physiological morphology, displaying aggregate structures or 
spheroids with prevalent cell junctions. Moreover, cells in 3D obtain phenotypic 
heterogeneity with a varied cell proliferation rate, gene expression and differentiation 
within one population [138]. Exposure to nutrients, growth factors, or drugs is also 
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heterogeneous where cells on the outer side of a spheroid are more exposed compared to 
cells in the inner core, which is more similar to in vivo conditions. In addition, cells in 3D 
have greater viability, less susceptibility to external factors, and show increased 
resistance to drug-induced stimuli [139, 140]. Lastly, both EMT or MET are processes 
that need the matrix for invasion during transition . Therefore, these processes are better 
modeled in 3D culture systems compared to standard 2D culture systems [141]. 
The critical component of the in vitro 3D microenvironment is the matrix or 
scaffold that supports cells, allows nutrient and signal exchanges among cells, and 
mimics ECM. Natural matrices such as decellularized tissue, collagen, laminin, fibrin, 
alginate, gelatine or cellulose acetate as well as synthetic or artificial matrices such as 
hyaluronic acids, polyethanol glycol, polyurethane, Alvetex, or MapTrix Hygels, are used 
in in vitro 3D systems [137]. In addition, biological or synthetic hybrids such as 
polycaprotactone (PCL)-collagen, PCL-gelatine, metals, ceramic and bioactive glass, and 
carbon nanotubes are also used as scaffolds in 3D cultures [136]. Typically, co-culture 
studies that interrogate the influence of other cell types are conducted in Transwell 
systems or direct co-culture, where physical interactions between the cells and 
microenvironment is missing [142, 143]. 3D culture systems are used in different 
applications such as pharmacological studies, drug testing, differentiation studies, tumor 
models, gene and protein expression studies [136]. 3D culture is an effective way of 
testing drug genotoxicity or cytotoxicity at an early stage of drug screening and is more 
cost effective and ethical when compared to animal models.  
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1.7 Regulation of breast cancer progression 
1.7.1 CD24 
Cluster of differentiation 24 (CD24) is a heavily glycosylated surface marker 
which is linked to the plasma membrane via a glycosylphosphatidylinositol (GPI) anchor 
and localized in membrane lipid rafts [144]. CD24 was first identified 4 decades ago in 
1978 [145]. CD24 is translated as a precursor protein of 76 or 80 residues in mice and 
human, respectively. Upon cleavage of the N-terminal signal sequence and C-terminal 
GPI anchor sequence, a mature peptide of 27 residues in mice and 32 residues in human 
is generated [144]. Since its initial discovery, sequencing efforts have revealed that CD24 
orthologues are present in many species. However, the conservation of CD24 over the 
course of evolution has not been reported nor has the earliest known ancestor carrying the 
gene been identified.  
CD24 is glycoprotein with varied molecular weight in different cell types, which 
is suggested to be due to glycosylation. Both Ser and Thr are potential sites for O-
glycosylation and asparagine is site for N-glycosylation [146]. N-glycan analysis of 
CD24 protein in lymphoblastoma, neuroblastoma and astrocytoma revealed the presence 
of fucosylated and sialylated complex [147]. 50% of amino acids in mature CD24 protein 
consists of O- glycosylation sites [146]. 
The diversity in CD24 glycosylation can potentially be explained by the 
alternative splicing that generates eight transcript variants. Most of them differ at 3’ UTR 
region and one of them lacks 5’ UTR region. Transcripts, CD24-001, CD24-201, and 
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CD24-002 are considered as known protein coding sequences that translates into CD24a 
isoform pre-protein and CD24-007 is considered as putative protein coding sequence that 
translates into CD24b isoform, whereas the other transcripts, 004, 005, 003 and 005 are 
predicted transcript variants that do not have any NCBI ref ID [148]. In mouse, CD24 is 
designated as CD24a, CD24b and CD24c which are located on chromosome 10, 8 and 
14, respectively. CD24a is very well studied, whereas CD24b and CD24c are considered 
as protein coding genes but nothing much is described about them. Moreover, CD24 
pseudogenes are present in both the mouse and human genome [149]. 
CD24 has various and diverse roles in cell adhesion and signaling, B-cell 
development, neuronal development, autoimmune diseases, and cancer [150]. In many 
cancers, such as colorectal, pancreas, and lung, high expression of CD24 is associated 
with enhanced proliferation, invasiveness and migration [82] and is also associated with 
metastasis. In stark contrast, forced expression of CD24 in CD24-/CD44+ breast cancer 
cell lines leads to a decrease in cell proliferation [151] and BCSCs with low expression of 
CD24 exhibit increased invasiveness and proliferation [79]. It has been shown that CD24 
expression is dynamically regulated in both CD24+ and CD24- cells, with CD24- cells 
gaining CD24 expression and vice versa in BC cells [74]. This dynamic regulation is 
associated with changes to the invasive phenotype and occurs both in vitro and in vivo 
[74]. 
Targeting the CD24-/CD44+ population reduces BC progression and metastasis 
[77, 152]. Inhibition of the Notch signaling pathway reduces the CD24-/CD44+ 
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population and brain metastasis from BC [153]. The anti-diabetic drug metformin, 
interestingly, regulates the EMT status in CD24-/CD44+ or CD24+/CD44+ cells [154] and 
also suppresses CD24 protein expression in TNBC [155]. In a similar manner, inhibition 
of the PI3K/Akt/mechanistic target of rapamycin (mTOR) pathway by quercetin 
suppresses the CD24-/CD44+ BCSC population [156]. Moreover, it has been previously 
shown that CD24-/CD44+ stem like cells can be generated from CD24+/CD44- cells after 
activation of the oncogenic Ras pathway [85], but it was not clear if this was a direct 
effect of Ras signaling or a secondary effect of the transformed phenotype.  
1.7.1.1 Regulation of CD24 
CD24 expression can be regulated transcriptionally or post-transcriptionally. 
Transcriptionally, regulation of the CD24 promoter depends on GC-rich regions. For 
example, the specificity protein 1 (SP-1) binding site, and nuclear factor of activated T-
cells 5 (NFAT5) binding sites were shown to promote transcription of CD24 in multiple 
sclerosis and hypertonicity of T-cells, respectively [157, 158]. Interestingly, the TWIST 
transcription factor family can upregulate or downregulate CD24 expression, with 
TWIST1 shown to downregulate CD24 transcription in BCSCs, and TWIST2 promoting 
CD24 transcription in human hepatocarcinoma [159, 160]. Moreover, the Wnt pathway 
represses CD24 via the T-cell factor 4 (TCF-4) transcription factor in mammary epithelial 
cells [161]. In addition, the CD24 promoter region contains a negative regulatory element 
(-983 to -1996 bp from transcription start site (TSS)) that can repress CD24 transcription 
via an unidentified transcription factor [162]. Bioinformatic analysis using the UCSC 
genome browser reveals a CpG island, a potential site for epigenetic silencing by 
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hypermethylation, between −828 to +430 bp, relative to the TSS [163]. Enhanced 
methylation of the CD24 promoter has been associated with decreased expression in 
glioblastoma cells and diseased conjunctiva [164, 165]. Post-transcriptionally, stability of 
CD24 mRNA depends on the two important cis elements in the 3’untranslated region 
(UTR). Deletion of either one of these elements leads to degradation of mRNA [166]. 
Destabilizing CD24 mRNA by deletion of a dinucleotide in the 3’UTR region leads to 
protection against autoimmune diseases [167]. Furthermore, the miR34a miRNA has 
been shown to repress CD24 mRNA expression via the 3’ untranslated region [168].  
1.7.1.2 Regulation of CD24 in breast cancer progression 
CD24 expression is highly dynamic in various cancers but the molecular 
mechanism involved in the regulation of its expression is poorly understood. Hormones 
such as estrogen in BC cells and androgens in urothelial cancer can suppress CD24 
expression [169, 170]. CD24 mRNA is up regulated by amino acid starvation in BC cells 
[171] while inhibition of signal transducer and activator of transcription 3 (STAT3) leads 
to dendritic cell mediated inhibition of CD24 in BC cells [172]. N- myc downstream 
regulated gene 2 (NDRG-2) down regulates CD24 in BC [173]. In addition, the 
expression of CD24 is upregulated by overexpression of terminal effector, truncated 
glioma associated oncogene homolog 1 (tGLI 1) of hedgehog pathway [174], and HIF1α 
binding to its promoter [175].  
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1.7.2 The Ras pathway 
 Ras is an oncogene with activating mutations present in approximately 30% of all 
human cancers, and is associated with poor prognosis [176]. The oncogenic role of Ras is 
very well established in many types of human cancers. Although, mutations in Ras are 
detected in only 5% of breast cancers, studies have shown that the epidermal growth 
factor receptor (EGFR)/Ras pathway is hyperactivated in >50% of TNBC [177, 178]. Ras 
activates numerous signaling pathways, such as the Raf, Ral guanine nucleotide 
dissociation stimulator (RalGDS), and PI3K pathways to promote a myriad of cellular 
functions such as cell proliferation, cell transformation and cell survival (Fig 1.5) [179]. 
Activation of RalGDS leads to activation of the RalA GTPases which leads to the 
subsequent activation of phospholipase D (PLD) to promote vesicle formation and 
membrane trafficking through the Golgi [180]. Activation of the Raf kinase downstream 
of Ras leads to the phosphorylation and activation of the MEK kinase (mitogen-activated 
protein kinase kinase 1), which subsequently phosphorylates and activates the mitogen 
activated protein kinase ERK (MAPK).The Raf/MEK/ERK pathway primarily regulates 
proliferation and apoptosis [181]. Activation of PI3K leads to phosphorylation of 
phosphatidylinositol phospholipids that recruit and promote the activation of Akt by the 
PDK1 (phosphoinositide-dependent kinase 1) and PDK2 (phosphoinositide-dependent 
kinase 2) kinases. The PI3K/Akt pathway promotes cell survival, growth, and metabolism 
in addition to regulating cell migration [181]. The PI3K pathway can also be activated 
independently of Ras activation and substantial cross-talk between the Raf and PI3K   
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Figure 1.5: Constitutive activation of Ras and its downstream targets: 
Receptor tyrosine kinases (RTK) are activated by growth factors such as epidermal 
growth factor (EGF) or transforming growth factor β (TGF-β). Ras is a small molecular 
weight G protein which is regulated by switching on and off by exchange of nucleotide 
guanine phosphate. It is in an active state when bound to guanine triphosphate (GTP) and 
an inactive state when bound to guanine diphosphate (GDP). Growth factor receptor 
bound protein (Grb2) facilitates the catalysis by guanine exchange factors (GEFs) such as 
son of sevenless (SOS) where GDP is replaced by GTP. Activated Ras activates several 
downstream pathways such as Ras/MEK, Ras/PI3K, Ras/RalGDS which further activate 
genes involved in cell growth, proliferation and differentiation. Ras is a small GTPase 
protein which has the ability to hydrolyse GTP to GDP. Ras is inactivated by Ras GTPase 
activating protein (GAP) protein, which hydrolyses GTP to GDP.   
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pathways has been established [181]. In addition, oncogenic Ras activation leads to 
evasion of immune response, increased angiogenesis, and microenvironment remodeling 
[182]. Consequently, oncogenic Ras contributes to loss of cell polarity, and tumor 
invasion. Ras dependent signaling pathways such as the Ras/MAPK, Ras/PI3K, Ras/RAL 
GTPase and Ras/Rho GTPase pathways play essential roles in metastatic progression 
[183]. Moreover, the oncogenic Ras pathway activation leads to an increase in the CD24-
/CD44+ BCSC population [85].  
1.7.3 EMT biomarkers 
The process of EMT and MET, and the markers involved in induction of 
metastasis have been discussed in section 1.3. Importantly, markers associated with 
epithelial-like or mesenchymal-like states can indicate the status of cancer progression. 
Induction of EMT leads to destruction of cell-cell junction proteins, namely E-cadherin, 
CD44, claudins, occludins, and zonula occludens1 (ZO1), and modification of 
cytoskeletal proteins such as vimentin, β-catenin, and actin. These transitions are 
regulated by EMT-TFs, which also have an essential role in cancer progression. 
Interestingly, several studies have shown that activation or inhibition of a single EMT-TF 
is sufficient to induce partial EMT in cancer cells [184].  
1.7.3.1 Cell-cell junction markers 
 Cadherins, specifically E-, N- and P-cadherin, are major components of epithelial 
cells. Loss of E-cadherin is a typical indication of EMT. Moreover, loss of E-cadherin is 
associated with the loss of cell differentiation and gain of invasiveness that leads to 
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metastasis [185]. In addition, a decrease in E-cadherin expression is significantly 
associated with basal-like or TNBC phenotype [186]. The switch from E-cadherin to N-
cadherin expression is an important indicator of EMT status [187].  
Integral transmembrane proteins such as claudins and occludin are important tight 
junction proteins that play a role in permeability and epithelial polarity [32]. In addition 
to cell polarity, tight junction proteins participate in different aspects of cancer 
progression. For instance, based on the claudin expression, a claudin-low molecular 
subtype of TNBC was identified. In the claudin-low BC subtype, claudins 3, 4, and 7 are 
suppressed with an associated increase in EMT characteristics [188]. Moreover, loss of 
claudin-7 is correlated to both histological high grade invasive ductal carcinoma and 
metastasis [189]. Silencing of occludin in BC cells leads to apoptotic resistance, 
suggesting a causative role in tumorigenesis [190]. Peripheral plaque proteins such as 
ZO-1, ZO-2, and ZO-3 are high in normal epithelial cells and maintain cell polarity. ZO-
1 and ZO-2 are dysregulated in breast tumor cells, which contributes to metastasis [191]. 
CD44 is a cell surface protein that participates in cell-cell interactions and also 
regulates cell signaling via receptor tyrosine kinases. It is also a biomarker for BCSC as 
mentioned earlier [69]. Metastatic cells show higher expression of CD44 than non-
metastatic cells. The CD44 variant (CD44v) isoform is switched to the CD44 standard 
(CD44s) isoform by epithelial splicing regulatory protein 1 during EMT, which is 
essential for promoting the EMT phenotype [192]. Broadly, cell-cell junction markers are 
not only correlated to initiation of EMT but also participate in overall BC progression. 
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1.7.3.2 Cytoskeletal markers 
 Vimentin is an intermediate filament protein present in mesenchymal cells that 
maintains cell integrity [193]. Vimentin is highly expressed in high grade invasive BC, 
and is correlated to invasion and poor prognosis of BC [194]. Downregulation of 
vimentin leads to impairment in migration and invasion of BC and colon cancer cells 
[195]. Switching between intermediate filament proteins is associated with cancer 
progression. For example, vimentin replaces cytokeratin in malignant BC cells [193]. The 
increase in vimentin is sufficient to induce changes in cell motility and shape typical of 
EMT [196]. Cortical organization of actin filaments is a hallmark of epithelial cells 
whereas actin stress fibers are detected in mesenchymal cells. Therefore, localization of 
actin is also an indicator of EMT status in cancer cells [197]. Depolymerization of the 
actin cytoskeleton leads to increase in E-cadherin expression and MET [198].  
β-catenin is known for maintaining cell integrity by linking cadherins to the actin 
cytoskeleton. β-catenin is key factor in the Wnt pathway, which is involved in EMT. 
Localization of β-catenin from the cell membrane to the nucleus also defines EMT status 
[199]. Upon activation of the Wnt pathway, β-catenin dissociates from E-cadherin and 
localizes to the nucleus, thus dysregulating cell integrity and promoting subsequent 
initiation of EMT [200]. Overall, reorganization of cytoskeletal proteins enhances cell 
motility and migration and allows the BC cell to participate in invasion. 
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1.7.3.3 EMT-TFs 
 EMT-TFs are crucial mediators of cellular plasticity, favoring metastasis. EMT-
TFs are complicated in cancer as they have additional functions that are tissue specific. 
For example, Snail initiates metastasis in BC progression whereas it has no effect on 
metastasis in pancreatic cancer [184]. EMT-TFs coregulate and functionally cooperate to 
target genes that enhance the mesenchymal phenotype and suppress the epithelial 
phenotype. Additionally, EMT-TFs activate MMPs 1, 9, and 14 to promote remodeling of 
the basement membrane and subsequent invasion [201]. The major EMT regulators are 
Snail, TWIST, and ZEB TFs, as mentioned earlier [202].  
 Overall EMT biomarkers act as major regulators of breast cancer progression and 
metastasis. Although, EMT-TFs are considered inducers of metastasis, the status of EMT 
can also be determined by the other EMT markers discussed above. 
1.7.4 Adipocyte-derived factors 
WAT is the major component of breast stroma and is known to contribute to BC 
progression, invasion and metastasis. Interaction between cancer cells and adipocytes 
leads to increased activity in adipocytes. Adipocytes activated by ovarian cancer cells 
show differential gene expression and changes in function that have been shown to 
contribute to tumorigenesis [203]. In addition, under obese conditions, adipocytes show 
elevated functional activity, leading to increases in factors related to pro-inflammation, 
hypoxia, angiogenesis, and ECM remodelling [204]. The adipocyte secretome is also 
modified when co-cultured with cancer cells, where an upregulation of MMP11, 
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osteopontin, TNF-α, and IL-6 has been observed [205]. Moreover, adipocyte cell size and 
cell number decrease when in the vicinity of the tumor compared to adipocytes that are 
distant from the tumor [206]. BC cells co-cultured with adipocytes in a transwell system 
also show reciprocal effects on adipocytes causing a decrease in lipid droplet (LD) 
number in adipocytes [207]. Moreover, there is an increase in fibroblast-like cells at the 
tumor site, suggesting a dedifferentiation of adipocytes [208].  
WAT is composed of mature adipocytes, and cells found in the stromal vascular 
fraction (SVF) that includes adipocyte-derived stem cells, pre-adipocytes, immune cells, 
and fibroblast cells. Mature adipocytes contribute to 80% of the WAT secretome and 
shares 60% of these proteins with SVF [209]. WAT as an endocrine organ secretes a 
variety of factors such as metabolites (see section 1.6.5), enzymes, hormones, growth 
factors and cytokines called as adipokines involved in communication with the 
surrounding environment for growth and development. So far, more than 100 adipokines 
have been evaluated, of which only a few are thoroughly studied including leptin, 
adiponectin, reisistin, visfatin, insulin-like growth factor (IGF), HGF, TGF, TNF-α, and 
IL-6 [209].  
1.7.4.1 Leptin 
Leptin regulates energy balance by inhibiting food intake and suppressing hunger. 
Under obese conditions, serum leptin concentrations are increased but often the receptors 
for leptin become dysfunctional and do not respond to leptin. Furthermore, dysfunctional 
leptin receptors leads to excess food intake and thereby excess fat accumulation. BC cells 
also express leptin receptors. Excess leptin can bind and induce proliferation and growth 
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of BC cells. Leptin also induces pro-inflammatory responses by activating monocytes and 
macrophages, thus contributing to chronic inflammation [210]. Leptin participates in the 
tumor progression of both ER positive and ER negative BC cell lines [211] and acts as 
growth factor that enhances IDC and ILC progression [212]. In addition, leptin regulates 
different aspects of cell growth such as the cell cycle, signaling pathways, and apoptosis, 
which all contribute to BC progression [213, 214]. Leptin receptor expression in TNBC 
promotes E-cadherin expression and supresses vimentin expression suggesting a role in 
promoting MET [215].  
1.7.4.2 Adiponectin 
Adiponectin plays an important role in regulation of lipid and glucose metabolism. 
Under obese conditions, adiponectin is decreased, thereby leading to an accumulation of 
lipids and glucose, which promotes insulin resistance and obesity. Adiponectin has anti-
inflammatory properties that modulate the inflammatory functions of immune cells and 
promote activation of anti-inflammatory macrophages [216]. Adiponectin supresses BC 
growth and invasion while enhancing apoptosis [217]. In addition, adiponectin inhibits 
PI3K activation and supresses cell proliferation. Adipocytes associated with cancer cells 
have been found to secrete low levels of adiponectin. [133]. Interestingly, a high leptin to 
adiponectin ratio is linked to increased risk of TNBC progression [218]. 
1.7.4.3 Other adipokines 
 IL-6 secreted by adipocytes not only regulates lipogenesis locally but also acts 
systemically [219]. Obesity leads to an increase of IL-6 in circulation, further adding to 
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inflammation [216]. Increased levels of IL-6 are correlated with poor prognosis, 
progression, and migration of BC [220]. TNF-α is an inflammatory cytokine and is 
primarily secreted by macrophages present in WAT. TNF-α is increased in TME and in 
obese humans, and an increase in TNF-α inhibits apoptosis of TNBC cells [216, 221]. 
Resistin is another adipokine shown to promote tumor growth, however, there is no direct 
link between resistin, obesity, and BC [222]. Autotaxin (ATX) is also secreted from 
adipocytes and is involved in fat expansion. ATX-lysophosphatidate signaling activates 
several cellular processes resulting in increased invasiveness and motility of  BC cells 
[107]. Obesity is associated with increased levels of circulating IGF-1 resulting in 
increased risk of many cancers including premenopausal BC. BC cells express IGF-1 
receptors, and binding of IGF-1 activates PI3K and MAPK pathways leading to cell 
proliferation [223–225]. Similarly, HGF is elevated by adipocytes during obesity and its 
receptor, c-Met, is expressed on BC cells, and their interaction during tumorigenesis 
leads to cell proliferation [226, 227].   
1.7.4.5 ECM proteins and remodelling 
 Adipocytes secrete a wide variety of ECM components, especially different types 
of collagens needed for mechanical support, that can also regulate adipogenesis [228, 
229]. Adipocytes are surrounded by basement membrane with collagen type VI and 
laminin as the major constituents [230]. Collagen type VI promotes the growth and 
survival of BC cells via NG2/chondroitin sulphate proteoglycan receptors [231] and the 
endotrophin component of the collagen VI protein promotes EMT and initiates metastasis 
[232]. 
44 
 
 Adipocytes also secrete matrix metalloproteinases such as MMP1, MMP7, 
MMP10, MMP11, and MMP14 which participate in remodelling the ECM [233]. MMP 
are also known as important regulators of tumor invasion, allowing cancer cells to 
migrate through the ECM. Specifically, expression of MMP11 induced in adipocytes by 
hepatocarcinoma cells promotes ECM remodelling and tumor invasion [234]. Moreover, 
MMP11 supresses adipocyte differentiation and enhances dedifferentiation, leading to an 
increase in fibroblast cells in the tumor microenvironment, which further amplifies tumor 
invasion [133]. 
Together, obesity and cancer completely change the gene expression and 
functional characteristics of adipocytes with reciprocal effects on cancer progression. 
Adipocytes communicate with cancer cells and can participate in the initiation of 
metastasis via secretory factors and ECM remodelling (Fig 1.6). The role of adipocytes in 
the colonization of tumors at local sites that can enhance micro-metastasis or at distant 
secondary sites is not well known. It is known that local adipocytes can trigger BC 
metastasis to the liver and lungs by paracrine signaling. Importantly, the presence of 
adipocytes at distant sites can intensify tumor metastasis, as in the case of bone marrow 
adipocytes [112, 113]. Bone marrow adipocytes secrete IL-1β, which is involved in the 
homing of BC cells to bone [235]. Therefore, adipocytes located at both the primary site 
and secondary sites can  play a crucial role in the process of BC metastasis.  
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Figure 1.6: Schematic illustration of role of adipocytes in different stages of cancer: 
Cancer associated adipocytes (CAA) contribute to tumor progression via secretory factors 
such as adipokines and via remodeling the ECM. Metabolites from lipolysis of CAA also 
contribute to cancer cells proliferation. CAA can induce systemic and local changes that 
leads to increase in inflammatory adipokines that contribute to metastasis to organs such 
as lungs and liver. Local adipocytes in bone marrow also release adipokines such as 
leptin and IL-1β that leads tumor cell homing to bone marrow. 
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1.7.5 Lipid metabolites 
Metabolic reprogramming is considered as an emerging hallmark of cancer cells 
[236, 237]. Cancer cells generate adenosine triphosphate (ATP) from aerobic glycolysis 
instead of mitochondrial oxidative phosphorylation; this change in metabolism is known 
as the Warburg effect [238]. The “reverse Warburg effect” is observed when cancer cells 
use the energy generated from stromal cells in the tumor microenvironment [239]. In 
addition to glucose, cancer cells take up free fatty acids and glycerol as a source of 
energy from stromal adipocytes. Martinez-Outshcoorn et al. [240] defined tumor cells “as 
metabolic parasites that rely on stromal sources for metabolic substrates such as lactate, 
glutamine and fatty acids via stimulation of glycolysis and lipolysis pathways in stromal 
cells”. Uptake of glucose metabolites in cancer progression is well acknowledged [241], 
however, the involvement of lipid metabolites has not been well defined.  
Reprogramming of lipid metabolism is part of the alterations in energy metabolism 
that occurs in cancer cells. Adipocytes regulate energy balance by storing triglycerides 
via lipogenesis and by production of diacylglycerol, monoacylglycerol, and free fatty 
acids via lipolysis within a cell. Highly proliferative cancer cells meet their energy 
requirements by synthesising lipids and cholesterol endogenously through lipogenesis or 
by obtaining them from the TME by stimulating lipolysis in adipocytes [229, 233]. To 
understand the adipocyte-tumor metabolic cross talk better, there has been an initiative 
for in vitro co-culture studies of BC cells and adipocytes or adipocyte-conditioned 
medium. Co-culture of adipocytes and BC cells increases lipolysis in adipocytes via 
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hormone sensitive lipase (HSL) and adipose triglyceride lipase (ATGL), resulting in 
release of free fatty acids that were transferred into adjacent BC cells as an energy source 
[243]. Moreover, a decrease in lipid droplet size and number has been reported in cancer-
associated adipocytes (CAAs). Free fatty acids can be used for mitochondrial β-oxidation 
or as metabolic substrates that supports cancer proliferation and migration. Increases in 
lipid metabolites are reported for many cancers such as breast, prostate, glioblastoma, and 
hepatocellular carcinoma [242]. For instance, fatty acid binding protein (FABP) family 
proteins are expressed on cells involved in active lipid metabolism. One of the FABP 
protein,  FABP4, which are involved in transport of fatty acids, are increased during BC 
progression [244].  
Additionally, cancer cells utilize lipids for cell membrane formation, generation of 
lipid-derived bioactive molecules, and generation of exosomes. Free fatty acids and 
glycerol released from lipolysis can be used for biosynthesis of membrane lipids during 
BC proliferation [245]. Bioactive lipids such as steroid hormones, diacylglycerol, 
eicosanoids, phospholipids and sphingolipids also participate in metabolic 
reprogramming of cancer cells [237]. The fatty acid receptor CD36 is involved in 
initiation of metastasis in breast derived tumors and is associated with poor prognosis 
[246]. Adipocyte-derived exosomes, also known as adiposomes, can stimulate cell 
invasion and migration in melanoma cancer cells [247].  
In addition to the tumor-stroma interactions mentioned earlier, reciprocal metabolic cross 
talk between adipocytes and BC not only drives pro-proliferative signaling but also 
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increases energy uptake by cancer cells. Previous literature has shownthat delipidation is 
observed in adipocytes co-cultured with cancer cells [206]. However, the mechanism 
involved in delipidation of CAAs is still elusive. 
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1.8 Hypotheses and objectives of this thesis 
Hypothesis 1: The CD24 gene is conserved among various species. 
Overall objective: Analyze the evolution of genomic structure and conserved peptide 
regions of CD24. 
Specific objectives: 
a. Determine the genomic structure and evolution of CD24 among various species. 
b. Determine the conserved regions of CD24 peptide among various species. 
Hypothesis 2: Oncogenic Ras downregulates CD24 promoter activity, mRNA, and 
protein expression independently via multiple downstream pathways to maintain 
the breast cancer stem cell population. 
Overall objective: Identify the mechanisms involved in the downregulation of CD24 by 
oncogenic Ras in a model system and in human breast cancer cells. 
Specific objectives: 
a. Determine the regulation of CD24 expression by the oncogenic Ras pathway in a 
model system. 
b. Evaluate promoter elements that repress CD24 transcription in response to 
constitutive activation of Ras. 
c. Determine the downstream targets of Ras that downregulate CD24 expression. 
d. Determine if inhibition of downstream targets, MEK, Raf and/or PI3K restores 
CD24 expression. 
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e. Identify the relationship between Ras pathway and CD24 gene expression in 
breast cancer subtypes. 
f.  Determine if inhibition of MEK or Raf restores CD24 expression in human breast 
cancer cell lines. 
Hypothesis 3: Mature adipocytes contribute to the mesenchymal-to-epithelial 
transition of BC cells via secretions in 3D co-culture system. 
Overall objective: Investigate the effect of reciprocal interactions between adipocytes, 
ECM and BC cells on mesenchymal-to-epithelial transition of BC cells in a 3D co-culture 
model. 
Specific objectives: 
a. Examine the effect of mature adipocytes on the morphology of mesenchymal 
TNBC cells. 
b. Determine if the mature adipocytes affect the mesenchymal to epithelial 
transition, stemness and proliferation of TNBC cells via adipocyte secretions. 
c. Determine the reciprocal effect of TNBC cells on adipocyte lipid content. 
d. Examine if the mature adipocytes affect the epithelial state of ER/PR positive BC 
cells. 
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Chapter 2. Materials and Methods 
2.1 Methods corresponding to Chapter 3 
2.1.1 Sequence and phylogenetic analysis 
The nucleotide sequences for 106 CD24 genes from 56 different species were 
obtained from the RefSeq Gene database (release 206, National Centre of Biotechnology 
Information (NCBI)) [148] and Ensembl genome database (release 25) (Appendix I) 
[248]. The DNA sequences corresponding to the mature peptide (lacking the signal 
sequence and the GPI-anchor signal sequence) were aligned with ClustalW multiple 
alignment using BioEdit software 7.2.5 [249]. Alignments were manually edited where 
needed and identities between sequence pairs were calculated (Supplementary file_1). 
For example, amino acids between 24-27 in tree shrew were creating gap when aligned 
with other species, these amino acids were deleted using BioEdit software. The 
evolutionary history of CD24 and CD24-like (as named in NCBI database) genes was 
inferred by using the Maximum Likelihood method [250] based on the Kimura 2-
parameter model [251], suggested as the best fitting model by model test analysis 
implemented in MEGA6 [252]. A discrete Gamma distribution was used to model 
evolutionary rate differences among sites (+G, parameter = 3.6287). All positions with 
less than 95% site coverage were eliminated. The robustness of branching was analyzed 
by the bootstrap method [253] with 1000 pseudo-replicates and a value greater than 60% 
considered as reliable. The human, mouse, and species present early in phylogenetic 
hierarchy such as turkey and green anole nucleic acid sequences corresponding to the 
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mature CD24 peptide were used to search for distant homologies via BlastN in the 
Ensembl database in platypus (Ornithorhynchus anatinus, version OANA5 [254]), 
opossum (Monodelphis domestica, version monDom5 [255]), Tasmanian devil 
(Sarcophilus harrisii, version Devil_ref v7.0 [256]) and wallaby (Macropus eugenii, 
version Meug1.0 [257]) genomes. 
2.1.2 CD24 protein structure predictions 
The CD24 pro-peptide and mature peptide consensus sequences were generated 
using BioEdit from the unique amino acid sequences (Supplementary file_2) and 
visualized using WebLogo [258]. These sequences were then analyzed by i-Tasser [259] 
and SPINE-D [260] for secondary structure predictions. 
2.2 Methods corresponding to Chapter 4 
2.2.1 Bioinformatics meta-analysis 
Microarray data were obtained from the Gene Expression Omnibus (GEO) 
repository [261] (Table 2.1). Data were analyzed as per the platform. Background 
correction and RMA normalization of the data were done using the Bioconductor 
package oligo (v 1.26.6) [262], using R (v 3.0) [263]. The data were analyzed by 
hierarchical clustering by gene and sample using Genesis (v 1.7.6) [264]. The percentage 
of probesets representing selected Ras pathway genes (H-Ras, K-Ras, N-Ras, M-Ras, R-
Ras, RAF1, ARAF, BRAF, MAPK1 (ERK2), PIK3C (phosphatidylinositol-4,5-
bisphosphate 3-kinase, catalytic subunits) A-G, PIK3R (phosphatidylinositol-4,5- 
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Table 2.1. Datasets used for meta-analysis. 
GEO 
Accession # 
Cell type/Cell 
line Treatment (n) Platform 
GSE26262 
[265]  
MDA-MB-231 siRNA against pin1 (3) 
siRNA against Lacz-control 
(3) 
siRNA against mutant p53 
(3) 
HG-
U133A_2 
GSE52262 
[266]  
MCF7 
HCC1954 
MC1 
MCF10A 
Normal patient 
cells 
SUM149 
SUM159 
CD24-CD44+, ALDH- (1) 
CD24-CD44+, ALDH+(1) 
CD24+CD44-, ALDH- (1) 
CD24+CD44-, ALDH+ (1) 
HG-
U133A_2 
GSE24592 
[267]  
 
MCF7 siRNA control vehicle – 4h 
(3) 
siRNA control – E2a – 4h (3) 
siRNA ERK2 vehicle – 4h 
(3) 
siRNA ERK2 – E2 – 4h (3) 
siRNA ERK1 vehicle – 4h 
(3) 
siRNA ERK1 – E2 – 4h (3) 
siRNA control vehicle – 24h 
(2) 
siRNA control – E2 – 24h 
(2) 
siRNA ERK2 vehicle – 24h 
(2) 
siRNA ERK2 – E2 – 24h (2) 
siRNA ERK1 vehicle – 24h 
(2) 
siRNA ERK1 – E2 – 24h (2) 
HG-
U133A_2 
GSE7561 
[224]  
 
MCF7 Serum free medium control – 
3h (3), 24h (3) 
IGF treated – 3h (3), 24h (3) 
HG-
U133A_2 
GSE5116 
[268]  
 
MCF-10F Untreated (3) 
Transformed by estradiol (3) 
Transformed outgrown cells 
(3) 
HG-
U133_plus_
2 
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aAbbreviations: E2-Estradiol, IGF-Insulin like growth factor, HT-Hydroxytamoxifen, 
ER-Estrogen receptor, RAR-retinoic acid receptor 
  
Xenografts of transformed 
cells (3) 
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bisphosphate 3-kinase, regulatory subunits) 1-6, RAL-A, RAL-B, and RalGDS) that 
clustered with CD24 was then calculated.  
2.2.2 Cell lines 
NIH/3T3 cells expressing the empty pBabe vector (Control), or the pBabe vector 
containing RasV12, RasV12S35, RasV12G37, or RasV12C40 (Table 2.2) were gifts from 
Dr. Kensuke Hirasawa, Memorial University [269]. All cell lines were maintained in 
Dulbecco’s Modified Eagle Medium (DMEM) supplemented with 10% fetal bovine 
serum (FBS), 1% anti-mycotic/antibiotic, 1% sodium pyruvate and maintained at 37°C in 
5% CO2. Control and RasV12 cells (2 x 10
5 cells/plate) were seeded in 35 mm plates. 
Based on the earlier studies and optimization in lab, cells were treated with the DMSO 
(dimethyl sulphoxide) vehicle control, 20 M U0126 and/or 100 M LY294002 
(Calbiochem-Millipore, Billerica, MA) in complete medium [270, 271]. 
2.2.3 RNA isolation and RT-PCR 
 Cells were lysed using 1 ml TRIzol (Life Technologies Co., Burlington, ON), 
then the lysate was mixed vigorously after adding 0.2 ml chloroform followed by the 
centrifugation at 12,000 g for 15 min. The clear aqueous layer is collected, followed by 
addition of 0.5 ml of isopropanol and incubated for 10-12 min. Then centrifuge at 12,000 
g for 10 min, discard the supernatant and add wash with 1ml 75% ethanol and centrifuge 
at 7,500 g for 5min. Remove the supernatant, air dry the pellet and resuspend in nuclease 
free water followed by DNase treatment using the Turbo DNA-free kit (Life 
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Technologies, Burlington, ON). RNA integrity was determined by running the sample on 
1% agarose gel. RNA (500 ng) was reverse transcribed to cDNA using MMLV-RT (Life 
Technologies, Burlington, ON) with random hexamers, and then amplified with Taq 
DNA polymerase (Norgen Biotek, Thorold, ON) using the primers (selected using primer 
blast based in protein coding region)shown in Table 2.3. The PCR products were 
visualized on a 1% agarose gel after staining with ethidium bromide. 
2.2.4 Quantitative RT-PCR (RT-qPCR)  
RT-qPCR was performed in triplicate using Maxima SYBR Green qPCR Master 
Mix (2X) (Thermo Scientific) for CD24 or RPLP0 using the primers shown in Table 2.3 
with the Eppendorf RealPlex2 Real Time PCR machine. RPLP0 for NIH/3T3 cell lines 
and GAPDH for MDA-MB-231 BC cells were used as housekeeping genes based on 
previous studies [272, 273] Relative CD24 mRNA levels were normalized using RPLP0 
or GAPDH were calculated using the ΔΔCt equation [274]. 
2.2.5 Fluorescent Activated Cell Sorting (FACS) 
Single cell suspensions (0.2 – 0.5 x 106 cells for NIH/3T3 derived cells) were 
obtained by scraping cells from plates into FACS buffer (1% heat inactivated FBS in 
phosphate-buffered saline (PBS, 137 mM NaCl, 2.7 mM KCl, 4.3 mM Na2HPO4, 1.4 mM 
KH2PO4, pH 7.4)). NIH/3T3 cells were incubated with 0.5 g anti-CD24 (M1/69), or rat 
IgG2a  isotype control, conjugated to APC (eBioscience, San Diego, CA, USA) for 30 
min on ice, followed by three washes with FACS buffer then fixed in 4%   
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Table 2.2 Cell lines used for regulation of CD24 by Ras pathway. 
NIH/3T3  
Cell line 
Vector transfected Mutation Constitutive 
activation of 
pathways  
Babe/Control Empty pBabe 
vector 
No mutation none 
RasV12 pBabe with RasV12 D12V- Aspartic 
acid 12 Valine 
 
Ras pathway 
RasV12S35 pBabe vector with 
RasV12 and S35 
T35S – Threonine 
35 Serine 
 
Ras-Raf pathway 
RasV12G37 pBabe vector with 
RasV12 and G37 
E37G- Glutamic 
acid 37 Glycine 
 
Ras-Ral Pathway 
RasV12C40 
 
pBabe vector with 
RasV12 and C40 
Y40C – Tyrosine 
40 Cysteine 
 
Ras-PI3K pathway 
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Table 2.3: Table showing the primers used in Chapter 4. 
Gene/Region Sequence (5’-3’) Efficiency Amplicon size 
RT-PCR 
mCD24 Forward -CTT CTG GCA CTG CTC CTA CC 
Reverse -AAC AGC CAA TTC GAG GTG GAC 
N/A 300bp 
mRPLP0 Forward -CGG CCC GTC TCT CGC CAG 
Reverse -CAG TGA CCT CAC ACG GGG CG 
N/A 448bp 
hCD24 Forward -AGA CGC CAT TTG GAT TGG GT 
Reverse -GCC AGC GGT TCT CCA AGC AC 
N/A 369bp 
hRas Forward -ATG ACG GAA TAT AAG CTG GTG 
Reverse -TCA GGA GAG CAC ACA CTT GCA 
N/A 570bp 
hGAPDH Forward -CCT GCT TCA CCA CCT TCT G 
Reverse -CCA TCA CCA TCT TCC AGG AG 
N/A 576bp 
RT-qPCR 
mCD24 Forward -ACT CAG GCC AGG AAA CGTCTCT 
Reverse -AAC AGC CAA TTC GAG GTG GAC 
1.07 109bp 
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mRPLP0 Forward -TCA CTG TGC CAG CTC AGA AC 
Reverse -AAT TTC AAT GGT GCC TCT GG 
1.03 101bp 
hCD24 Forward -GAG CCA GCG GTT CTC CAA GCA 
Reverse -CTG CCC ATG TCC CCT CCG TC 
1.11 71bp 
hRPLP0 Forward- TGG ATG ATC TTA AGG AAG TAG 
TTG G 
Reverse – GCG TCC TCG TGG AAG TG 
1.02 119bp 
Promoter Amplification 
-688/+1 Forward -GTT GGA TGC TCC CGG GTA TGG 
Reverse -GGA GCG CGG CCG GCC GGC GG 
N/A 688bp 
aAbbreviations: N/A – Not applicable.   
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paraformaldehyde. Data were collected with a FACS Calibur (BD Biosciences, 
Mississauga, ON, Canada) and percentage of cell population expressing the protein on 
cells were analyzed using FlowJo software v10.0.5 (Ashland, OR, USA). 
 
2.2.6 Western blot analyses 
Cells were washed with PBS and then lysed in RIPA buffer (50 mM Tris-HCl (pH 
7.6), 0.02% sodium azide, 0.5% sodium deoxycholate, 0.1% SDS, 1% NP-40, 150 mM 
NaCl) containing 1 µg/ml aprotinin, 1 mM PMSF and 1X HALT phosphatase inhibitor 
cocktail (Thermo Scientific, Waltham, MA, USA). Protein concentration was determined 
using a Bicinchoninic acid (BCA) protein assay (Thermo Scientific). The samples were 
subjected to 10% SDS polyacrylamide gel electrophoresis, followed by transfer 
procedure where the gel and nitrocellulose membrane are sandwiched between the filter 
paper and sponges and the current is passed in a way that the proteins are transferred 
from gel to the membrane, which was blocked in 5% skimmed milk in Tris-buffered 
saline (10 mM Tris base, 150 mM NaCl, pH 7.5) and 0.05% Tween-20 (TBST) for 1 hr. 
Primary antibodies to detect phosphorylated ERK (1:5000) (Cat #9101), phosphorylated 
Akt (1:2000) (Cat #9271), total ERK (1:5000) (Cat #4695), and total Akt (1:2000) (Cat 
#9272) were obtained from Cell Signalling Technologies, Inc. (Danvers, MA, USA). 
Goat anti-rabbit-HRP (1:2000) (Santa Cruz Biotechnology Inc (Dallas, TX, 
USA))secondary antibody was used for all the primary antibodies mentioned above  . 
Both the primary and secondary antibodies were diluted in 5% bovine serum albumin in 
TBST. After blocking membrane was incubated with desired primary antibody for 
63 
 
overnight at 4° C, followed by the 3X washes for 10 min at RT. Then the membrane was 
probed with secondary antibodies for 1 hr at RT, followed by the 3X washes as 
mentioned above. Immobilon Western Chemiluminescent HRP substrate was used for 
detection (EMD Millipore, Darmstadt, Germany) followed by imaging with the 
ImageQuant LAS 4000 (GE Healthcare, Morgan Boulevard, Baie d’Urfe Quebec, 
Canada). 
2.2.7 CD24 promoter analysis 
Genomic DNA was isolated from a male C57BL/6N mouse liver using the 
Genomic DNA isolation kit (QIAGEN, Germantown, MD, USA). The CD24 promoter 
region from -688 to -1 from the TSS (p688) was amplified from genomic DNA with the 
GC-Rich PCR system (Roche, Basil, Switzerland) using the primers indicated in Table 
2.3. The promoter was cloned into the HindIII and BglII sites of the pGL4.17 vector 
(Promega, Madison, USA). The deletion constructs -469 to -1 (p469), -357 to -1 (p357) 
and -168 to -1 (p168) were generated using the Erase-a-base kit (Promega) according to 
the manufacturer’s instructions. Briefly, p688 promoter was linearized by restriction 
digestion followed by digestion with of S1 nuclease reaction mix at 37° C. The nuclease 
digestion was stopped every 30 secs by collecting 2.5 µl of sample and mixing with Exo-
III, digestion proceeds at about 450 bases/minute. The digested samples will be 
precipitated, and cleaned followed by re-ligation, and transformation. The positive 
colonies were selected followed by plasmid isolation. All sequences were verified by 
sequencing at The Centre for Applied Genomics (Toronto, ON, Canada). 
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The E-box elements on the p688 promoter region were mutated using the site 
directed mutagenesis kit (Promega) according to manufacturer’s instructions. Briefly, 
every nucleotide in consensus sequence of the two E-box elements were checked for any 
change in the TF binding regions and selected the CACCTG→CGCCTG for E-1 and 
CACTTG→GACTTG for E-2 sequence. The mutations lead to one additional TF binding 
region on both E-1 and E-2 that are involved in regulation of cell cycle regulation and 
leukemia inhibitory factor, respectively. The primers were designed based on these 
mutations and amplified the p688 plasmid using these primers using the site directed 
mutagenesis kit. Amplified product was treated with DpnI to remove template, followed 
by transformation into XL-10 Gold ultra competent cells. The positive colonies were 
selected followed by plasmid isolation. All sequences were verified by sequencing at The 
Centre for Applied Genomics (Toronto, ON, Canada). 
 NIH/3T3 cells expressing empty vector (control) or RasV12 cells (30,000 
cells/well in 24-well plates) were transfected with 1 µg of the pGL4.17 vector with or 
without the CD24 promoter regions and 20 ng pRL-SV40 vector (Promega) using 2.5 µl 
Superfect transfection reagent (Qiagen), following the manufacturer’s instructions. After 
24 h, cells were lysed with 1X Passive Lysis Buffer and Firefly and Renilla Luciferase 
activity were measured using the Dual-Luciferase Reporter Assay kit (Promega). 
2.2.8 Statistical analysis 
Statistical analysis was performed in R v.3.3 [275] accessed through RStudio [276] 
(Appendix II). Significant differences in CD24 mRNA between experimental conditions 
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were determined by Student’s t-test or One-Way ANOVAs with Tukey Honest 
Significant Differences (HSD) post-hoc analysis. Significant differences in CD24 surface 
protein expression were determined by One-Way ANOVA with Tukey HSD post-hoc 
analysis between the conditions. Differences were considered statistically significant at 
P<0.05. 
2.3 Methods corresponding to Chapter 5 
2.3.1 Cell lines  
3T3-L1 pre-adipocytes (American Type Culture Collection, Burlington (ATCC), 
Burlington, ON) were maintained in high-glucose DMEM (Life Technologies Co, 
Burlington, ON) supplemented with 10% newborn calf serum and 1% 
penicillin/streptomycin (DMEM/NCS). MDA-MB-231, SUM159, Hs578t, and MCF7 
cell lines were obtained from ATCC and maintained in Roswell Park Memorial Institute 
(RPMI) 1640 Medium (Life Technologies) supplemented with 10% FBS and 1% 
penicillin-streptomycin. All cells were confirmed to be mycoplasma-free using the 
MycoAlertTM Plus Mycoplasma Detection Kit from Lonza (Basel, Switzerland). The 
breast cancer cell lines were authenticated by STR profiling by The Centre for Applied 
Genomics (The Hospital for Sick Children, Toronto, Canada). After thawing, all of the 
cell lines were used for up to 15 passages.  
 3T3-L1 cells were grown to confluency in 4-well chamber slides and 
adipogenesis was induced as previously described [272]. Briefly, pre-adipocytes were 
grown to confluency and then initiation medium containing 0.5 mM 3-isobutyl-1-
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methylxanthine and 1 μM dexamethasone (Millipore, Darmstadt, Germany) in DMEM 
supplemented with 10% FBS (as it has additional growth factor and protein composition 
compared to NBCS that aids in adipogenesis) and 1% penicillin/streptomycin 
(DMEM/FBS) was added to the cells 48 h post-confluency. Initiation medium was 
replaced with progression medium (10 μg/ml insulin (Sigma-Aldrich, St. Louis, MI, 
USA) in DMEM/FBS) after 48h followed by replacement with DMEM/FBS 48h later. To 
obtain conditioned medium (CM), adipocytes were differentiated for 5 days and the 
medium collected 48 h after Matrigel was overlaid. Medium was refreshed and CM was 
collected again 48 h later. CM was mixed 1:1 with fresh medium and added to the breast 
cancer cells overlaid on Matrigel on day 6 and 8. Adipocyte and CM co-cultures were 
maintained for 5 days, and pre-adipocyte co-cultures maintained for 4 days, after plating 
BC cells on Matrigel. Note that there were no differences in colony structure or protein 
expression in breast cancer cells cultured on Matrigel for 4 or 5 days in the control 
cultures. 
2.3.2 3D co-culture 
We modified the 3D culture method initially developed by Dr. Mina Bissell [135] 
and adapted by Debnath et al. [277], as follows (Fig 2.1A). 3T3-L1 cells were 
differentiated for five days, at which point  lipid droplets were clearly observable in 
>60% of the cells. On day six, 110 l of Matrigel (9.1 mg/ml, BD Bioscience) was 
overlaid on top of mature adipocytes, or empty wells of a 4-well chamber slide and 
allowed to set for 1 h (Fig 2.1A). MDA-MB-231/ MCF7 (13,500 cells/450 µl), SUM159 
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(11,250 cells/450 µl), or Hs578t (18,000 cells/450 µl) were overlaid and incubated with   
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Figure 2.1 Schematic representation of the 3D co-culture system. 
(A) Pre-adipocytes (3T3-L1 cells) are differentiated into mature adipocytes on 
chamber slides for five days. On day six, BC cells are overlaid in laminin-rich 
Matrigel and cultured in 3D for five days with 50% medium replacement every 
48 h. Immunofluorescence detection of protein markers in the BC cells and direct 
staining for lipid droplets in the adipocytes was performed on day 11. (B) A 
representation of the morphology of BC cells used in this study when grown in 
3D culture using Matrigel. MDA-MB-231 and Hs578t cells have stellate 
morphology, SUM159 cells adopt grape or mass-like structures, and MCF7 cells 
form round/mass-like structures [135, 278].  
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co-culture medium (mammary epithelial basal medium (MEBM) (Promo Cell, 
Heidelberg, Germany) containing epidermal growth factor (10 ng/ml), insulin (5 µg/ml), 
hydrocortisone (0.5 µg/ml), bovine pituitary extract (0.4%) and 2% Matrigel). BC cells 
were grown for an additional four-five days to allow colony formation. For the pre-
adipocyte co-culture, pre-adipocytes were plated on day five, allowed to undergo growth 
arrest for 48 h, and then Matrigel and breast cancer cells were overlaid on day seven. 
2.3.3 Immunofluorescence (IF) 
Cells were fixed with 4% paraformaldehyde for 20 min at room temperature, followed by 
permeabilization in 1X PBS containing 0.5% Triton X-100 for 10 min at 4°C, then 
washed three times with PBS-glycine (100 mM glycine in 1X PBS) and blocked With 
10% donkey serum in IF buffer (0.1% BSA, 0.2% Triton X-100, 0.05% Tween 20, 1X 
PBS) for 1 h at room temperature. Primary antibodies were diluted in blocking buffer as 
mentioned in the paragraph below, incubated overnight at 4°C and detected with 
appropriate secondary antibodies. Before and after secondary staining (as mentioned in 
the paragraph below), cells were washed three times with IF buffer. Co-cultures were 
then stained with 4’,6-diamidino-2-phenylindole (DAPI) (Life technologies) and/or 
boron-dipyrromethene (BODIPY) 493/503 (Life Technologies) for LD detection for 25 
min at room temperature, then washed once with 1X PBS. The chambers were separated 
from the slide according to manufacturer’s protocol and any excess 1X PBS was gently 
removed. An even bead of silicone sealant (GE, Boston, MA, USA) was applied around 
the Matrigel layer to avoid compression of co-cultures by coverslips. Prolong Gold (Life 
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technologies) was used for mounting slides and placed in dark at room temperature to dry 
overnight. The slides were imaged using 20X and 40X objectives with the Nikon A1 
confocal microscope with NIS elements imaging software.  
Primary antibodies and dilutions used were as follows: vimentin (1:200; Cat 
#V2258; Sigma-Aldrich, St. Louis, MO, USA), ZO-1 (1:50; Cat #SC33725; SantaCruz 
Biotechnology Inc. Dallas, TX, USA), E-cadherin (1:200; Cat #610181; BD Biosciences, 
Franklin Lakes, NJ, USA), claudin7 (1:200; Cat #AB27487; Abcam, Cambridge, UK), 
CD24 (1:100; Cat #NBP1-46390; Novus Biologicals, Littleton, CO, USA), CD44 (1:25; 
Cat #M708201-2; Dako), and Ki67 (1:100; Cat #M724029-1; Dako, Denmark). 
Secondary antibodies used were AlexaFluor-647 anti-rat IgG (Cat #712-605-153; 
Jackson Immunoresearch Laboratories, West Grove, PA, USA), AlexaFluor-647 anti-
rabbit IgG (Cat #711-605-152; Jackson Immunoresearch Laboratories), and DyLight 594 
anti-mouse IgG (NBP1-75617; Novus Biologicals). 
2.3.4 Image analyses 
Colony morphologies were assessed by analysis of circularity using ImageJ v. 
1.48 [279]. Structures present in three images per replicate (minimum 10 structures per 
replicate) were traced manually and the circularity measurement was obtained. A 
circularity value > 0.7 was classified as round/mass-like, 0.7-0.2 was classified as grape-
like, and < 0.2 was classified as stellate (Fig. 2.1B). 
Protein expression was analyzed using ImageJ by measuring the intensity of 
fluorescence of the whole image. Integrated density (IntDen) was determined to capture 
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the total fluorescence of each marker. Background was subtracted by taking 
measurements of selected areas where cells were absent as observed from the respective 
bright field images. The total fluorescence intensity of each marker was determined by 
normalizing IntDen of each marker to IntDen of DAPI and then the relative IntDen 
values of each marker per condition was determined relative to the control. 
ImageJ was used to analyze the number and size of LDs [280] from five 
independent fields of view per biological replicate, where images from five different 
depths (Z-stack) were condensed to form a single 2D composite image of all BODIPY 
493/503 stained LD. The composite image was converted to an 8-bit binary image 
followed by automatic threshold adjustment and then a watershed-based separation of 
closely spaced LD applied before calculation of LD area and number. The analyze 
particles command was used to measure the area and number of LD in ImageJ.  
2.3.5 Statistical analysis 
Statistical analysis was performed in R v.3.3 [275] accessed through RStudio 
[276] (Appendix II). Significant differences in lipid droplet area distributions between 
each experimental condition were determined using the Kolmogrov-Smirnov test. 
Significant differences in lipid droplet number were determined using a Student’s t-test. 
Differences in the distribution of colony shape was determine by 2 analysis between 
control and experimental conditions. Significant differences in specific colony shape 
were determined using a 4 X 3 between subjects factorial ANOVA, followed by one-way 
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ANOVAs and Tukey HSD post-hoc analysis within each shape between conditions. 
Differences were considered statistically significant at P<0.05. 
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Chapter 3. Analysis of CD24 structure and evolution 
CD24 is known for its diverse biological roles in cell differentiation and 
development [150]. However, little is known about CD24 genomic structure, 
conservation and evolution. Since its initial discovery, sequencing efforts have revealed 
that CD24 orthologues are present in many species. In addition, transcript variants of 
CD24 in human have been recently identified [148], and CD24 pseudogenes are present 
in both the mouse and human genomes [149]. However, the conservation of CD24 over 
the course of evolution has not been reported nor has the earliest known ancestor been 
identified. Therefore, here I have performed a phylogenetic analysis of the CD24 gene. 
These analyses demonstrate that the sequence of the mature CD24 peptide, but not the 
genomic structure, is well-conserved from reptiles and birds through to mammals, and it 
suggests that glycosylation sites drive this conservation.  
3.1 CD24 genomic structure is diverse but the coding sequence is conserved.  
The CD24 gene has been well characterized in both the mouse and human 
systems at the functional and genomic levels [281], however, very little is known about 
CD24 in other species. CD24 homologue sequences, which were generally annotated as 
CD24 or CD24-like (CD24L) with predicted genes given either designation, were thus 
analyzed. 
 Analysis of the genomic structure of 106 genes from 56 different species 
representing 17 unique orders (Appendix I) revealed that there are 5 general types of 
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structures based on the organization of introns and exons, and the presence of 
untranslated regions (UTRs) in the CD24/CD24L gene (Fig. 3.1). The first type consisted 
of one protein-coding exon lacking UTRs, while the second type consisted of one 
protein-coding exon along with either a 5’-UTR or both 5’- and 3’-UTRs (Fig. 3.1A-B). 
The third type consisted of 2 protein-coding exons lacking UTRs, while the fourth type 
also had 2 exons but also contained either both UTRs or a 3’-UTR (Fig. 3.1C-D). The 
fifth type had 3 exons with or without UTRs (Fig. 3.1E). 
 The designation of CD24 or CD24L appeared to be unrelated to the genomic 
structure, as an approximately equal number of each designation possessed each type of 
genomic structure. The group with 2 exons contained the most evolutionarily diverse 
species of all the groups (Fig. 3.1D). Neither the ancestral genomic structure of CD24 nor 
when the various gene structure types evolved could be determined. It appears that some 
CD24 genomic structure variants might have lost introns and/or UTRs and others might 
have gained additional introns. Moreover, the evolutionarily higher organisms, such as 
human, marmoset, and green monkey, were more likely to have gained the additional 
exon (Fig 3.1E). 
 CD24 is translated as a precursor protein of approximately 80 amino acids, 
depending on the species. In human, mouse, and rat, three distinctive regions of the CD24 
precursor protein can be identified: the signal peptide for endoplasmic reticulum 
(ER)/golgi localization, the mature core peptide, and the GPI anchor peptide [144, 282].  
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Figure 3.1: Genomic structure of CD24 orthologues. 
Species with CD24 and CD24-like (CD24L) genes are listed on the right of the 
representative gene structure. Labels with ‘v’ followed by number represent transcript 
variant numbers while ‘L’ followed by numbers represent paralogues of CD24L genes 
within a species. The genomic structures shown are (A) one protein-coding exon with no 
untranslated regions (UTRs), (B) one protein-coding exon with 5’- and/or 3’-UTRs, (C) 
two protein-coding exons with no UTRs, (D) two protein-coding exons with 5’- and/or 
3’-UTRs, and (E) three protein-coding exons with or without UTRs. Exons are shown as 
boxes, with protein coding regions in black and UTR regions in white. 
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As with all GPI-anchored proteins, the signal peptide and GPI-anchor peptide are lost 
prior to surface expression of CD24. This processing generates the mature peptide, which 
ranges from 26 to 41 residues with a mean and median length of 32 residues. To assess 
the evolutionary history of CD24 genes, we analyzed the nucleic acid sequences coding 
for the mature core peptide. Overall, we found 34 orthologues for human CD24 
distributed across 26 species, including reptiles, birds, and placental mammals. Within 
these genes, transcript variants were identified in 4 species (human, marmoset, Sumatran 
orangutan, and green monkey) (Fig 3.2). In the remaining 22 species, the sequences were 
annotated as CD24L; 14 of these had paralogues identified at different locations in the 
genomes (Appendix I). No sequences with similarity to CD24 were identified in the 
available marsupial or monotreme genomes.  
 Two clear branches that divide reptiles and birds from placental mammals were 
resolved on the phylogenetic tree (Fig. 3.2). Despite the low bootstrap numbers, which 
are most likely due to the short length of the alignment, sequences tended to be organized 
by taxonomic order. Some exceptions were observed such as for the sequences retrieved 
from galagos, which did not cluster together with sequences from other primates. We 
found that the CD24L genes were not phylogenetically distinct from the CD24 genes, 
indicating that these should not be distinct classifications. Furthermore, in some species, 
such as the naked mole rat, all CD24L genes were in one clade, while CD24L genes from 
other species, such as dolphin and whale, were present in separate clades. In some 
species, such as the prairie deer mouse, gibbon, and hedgehog, both a CD24 gene and a 
CD24L gene were present in the same clade. 
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Figure 3.2: Phylogenetic analysis of the nucleotide sequence encoding the mature 
CD24 peptide. 
Sequences are labeled as described for Figure 1. The triangular shaped branches represent 
multiple sequences from the species indicated, where the size of the triangle is relative to 
the number of sequences present. The order and class of each species are shown on the 
right. Bootstrap values above 60% are shown. 
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No strict correlation between the genomic structure and the phylogenetic 
relationship amongst sequences could be detected. We observed that all genes identified 
from birds and reptiles, whose sequences form a separate clade, possessed the same 
genetic structure. However, we cannot rule out the possibility that other genome 
structures may exist in these groups and will be identified as more detailed genome 
annotations become available. In most cases, all sequences from the same species or 
order of animals clustered together in spite of possessing different genomic structures. 
For example, three different gene structures were found in gibbon (Fig. 3.1A, B and E) 
but all of these sequences clustered together in the tree (Fig. 3.2). The same pattern could 
be observed for most of the primates. This might suggest that the duplication of the 
original CD24 sequence occurred after the separation of the lineages. However, in other 
cases sequences from the same species but with different gene structures appeared in 
separate clusters, such as for common bottle-nosed dolphin. These observations suggest 
that some duplications might also have occurred before the separation of some lineages. 
Overall, it appears that CD24 orthologues and paralogues have evolved through a 
combination of both evolutionarily recent and distant within-lineage duplications. 
3.2 CD24 peptide organization and structure 
Note: Analysis in this section was performed by Craig Ayre, while interpretation was 
performed in collaboration. 
The consensus sequence of CD24 derived from the alignment of the previously 
analyzed species was used to predict secondary structure and organization at the protein 
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level. The consensus sequence was longer than the sequence for any individual species as 
it includes rare and unique amino acid insertions from each species added into the single 
sequence. Secondary structure prediction of the precursor CD24 protein using i-Tasser 
suggested that there are two alpha-helical regions (Fig. 3.3A). One is in the N-terminal 
region, from residues 3 to 29, which corresponds to the signal sequence. The second is in 
the C-terminal domain, from residues 86 to 96, which corresponds to a portion of the 
GPI-anchor signal sequence. No secondary structure could be predicted for the region of 
the precursor protein that corresponds to the mature peptide between residues 42 to 77. 
As the N- and C-terminal regions are cleaved from the mature peptide during post-
translational processing [150], we also analyzed the mature core peptide in isolation (Fig. 
3.3B). Similarly, no discrete secondary structure was predicted for the mature peptide in 
isolation. As expected from the secondary structure prediction results, no tertiary 
structure was confidently predicted for either the precursor or the mature peptide. 
In agreement with the secondary structure prediction, analysis of the intrinsic 
disorder of the CD24 precursor protein via SPINE-D revealed that this protein is likely to 
be highly intrinsically disordered, with an average probability score of 0.62 (Fig. 3.3A). 
In the N-terminal region of the precursor protein, the region from residues 24 to 37 has a 
probability of disorder of 0.32, indicating it is likely an ordered region. This area partially 
overlaps with the alpha-helical domain predicted by i-Tasser (Fig. 3.3A). In the C-
terminal region, there is another ordered region from residues 88 to 97, with a probability 
of disorder of 0.42, overlapping with the predicted alpha-helical region of the GPI-anchor 
signal sequence. The central domain of the precursor protein containing the mature core   
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Figure 3.3: Visualization of CD24 secondary structure motifs and sequence 
alignment. 
The predicted secondary structures of the CD24 (A) pro-peptide and (B) mature peptide 
were assessed using i-Tasser and SPINE-D. The predicted disorders of the pro- and 
mature peptide are represented with a blue line. Areas predicted by i-Tasser to contain 
alpha-helical domains are shown in green. Black bars represent the average probability of 
disorder predicted by SPINE-D for two ordered domains in the N- and C-terminal regions 
and the mature peptide. (C) A graphical representation of the mature CD24 peptide 
alignment is shown. Letter height indicates relative abundance of a given amino acid in 
each position. Error bars show a Bayesian 95% confidence interval. Asn and Arg residues 
are shown are red, while Ser and Thr residues are shown in orange. Hydrophobic amino 
acids are in blue and all other amino acids are in black. Known Mus musculus N-
glycosylated residues are indicated with * and known O-linked glycoslyations are 
indicated with °. Potential N-linked glycosylation sites are shown with +, based on the 
Asn x(Ser/Thr) glycosylation motif. Amino acid positions 14 and 21-24 are shown as 
gaps as they do not align or are not present in the majority of sequences analyzed 
(Supplementary file_2). The likelihood of a given residue existing in a disordered state 
was predicted using SPINE-D and the probability of disorder is shown above the 
sequence. 
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peptide from positions 42 to 77 had a high average probability of disorder value of 0.80. 
Furthermore, when analyzed in isolation, we found that the intrinsic disorder of the 
mature peptide increased to an average of 0.94, primarily due to a loss of order at the N-
terminus (Fig. 3.3B). Therefore, post-translational processing of the CD24 protein causes 
reduced order in the peptide core, however, it is not precisely known how the addition of 
glycosylations and/or the GPI-anchor influence the structure or disorder of the surface 
protein. 
Visualization of the alignment of the mature core peptide clearly reveals that 
several of the known O-glycosylation sites, as well as known and predicted N-
glycosylation sites [146], are highly conserved (Fig. 3.3C). Specifically, there were 12 
highly conserved Ser or Thr residues that could be modified by O-linked glycosylation, 
and five highly conserved Asn residues that can be N-glycosylated, based on the 
consensus sequence of Asn-X-(Thr/Ser) where X can be any amino acid except proline 
[283]. Of the potentially glycosylated residues, there are three highly conserved residues 
that are known to be N-linked, and four highly conserved residues that are likely to be O-
linked, at least in the case of erythrocyte-derived mouse CD24 [284] 
In addition to the glycosylation sites, there are two clearly identifiable regions 
with highly conserved sequences, from positions 9 to 19 and 28 to 35 of the mature 
protein. The second, a proline-rich region, partially overlaps with the CD24 domain as 
annotated by the Pfam database (PF14984) [285], which begins at position 26 and ends 
within the GPI-anchor signal peptide at position 75. However, as the Pfam domain 
PF14894 includes the GPI-anchor peptide, it does not accurately represent the mature 
core peptide. Nevertheless, the high conservation of key glycosylation residues supports 
previous work showing that glycosylation of CD24 dictates ligand specificity and 
therefore function of CD24 [286–288]. 
85 
 
3.3 Discussion 
This is the first comprehensive analysis of CD24 with regards to its distribution, 
genomic structure, and evolution. Although the mature CD24 peptide is only between 26 
and 41 residues, it was possible to use phylogenetic analysis to evaluate the evolutionary 
relationships amongst the CD24 genes from 56 species. The evolution of the CD24 
genomic structure has been dynamic, with apparent gains and losses of intronic regions as 
well as UTRs. However, there was no correlation between the presence or absence of 
either the intronic regions or the UTRs and the evolutionary relationships of the species 
with CD24 genes. The CD24 3’-UTR can regulate CD24 transcript stability in COS cells 
[166] and intronic regions can contain regulatory regions that regulate expression level. 
Therefore, further investigation of these regions and their role in regulating CD24 
expression may reveal novel regulatory mechanisms and clarify the role and evolution of 
these non-coding sequences. 
 This analysis provides evidence that CD24 arose prior to the divergence of 
reptiles and birds from mammals approximately 200 million years ago [289], with 
subsequent loss of the gene from non-placental mammals. The CD24 gene was not 
annotated in any of the monotreme or marsupial genomes, nor were we able to detect it 
using the human, mouse, turkey or green anole CD24 mature peptide sequence as the 
query. There are two possibilities to explain the absence of the CD24 gene in these 
animals. The first is that the CD24 genes were not represented in the genomes currently 
available from these species and that with further sequencing efforts CD24 orthologues 
will be found. The second possibility is that CD24 was lost in an ancestor of the non-
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placental mammals. While this possibility is intriguing given the presence of CD24 in the 
placenta [290] and on vesicles secreted into the amniotic fluid from the fetus [291], the 
presence of CD24 in egg laying reptiles and birds does not support a divergent role of 
CD24 in placental-based gestation. Further work is necessary to determine if the function 
of CD24 is conserved in egg-laying animals, as well as to investigate potential roles of 
CD24 in placenta-based gestation. There is currently limited availability of CD24 
sequences from birds and reptiles (three and one, respectively) and therefore the 
evolutionary history of this gene in these groups is not clear. 
Analysis of the predicted structure of the consensus mature peptide sequence did 
not reveal any secondary structure for CD24. As such, CD24 may be considered an 
intrinsically disordered protein. Intrinsically disordered proteins represent a 
comparatively new paradigm in understanding protein structure and the suggestion is that 
many proteins exist without a defined secondary or tertiary structure as a basis of their 
molecular function [292]. Protein functions thought to depend on intrinsic disorder 
include flexible linker domains and phosphorylation sites [292, 293]. Given that CD24 is 
heavily glycosylated in its mature form, it is also plausible that this disorder gives the 
mature protein additional flexibility to maximize its glycosylation potential through 
minimizing steric interactions. The glycosylations may also impose order on the 
structure, thereby making structure prediction from the amino acid sequence alone not 
possible. 
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As mentioned, the amino acid sequence of CD24 possesses conserved 
glycosylation sites, as well as a proline-rich domain near the C-terminal region of the 
mature peptide. The conservation of glycosylation sites strongly suggests that they are 
critical regions that define the biological activity of CD24, including the localization of 
CD24 to the extracellular surface of the plasma membrane. Interestingly, the sites and 
degree of glycosylation can also vary within and between species. For example, the 
comparison of CD24 between humans and mouse reveals human CD24 is enriched in Ser 
and Thr, and missing two Asn residues, compared to mouse [287]. This may result in 
greater O-linked and fewer N-linked glycosylations. The mature core protein only 
contributes approximately 3.5 kDa, with the remaining and variable mass of CD24 made 
up by differing glycosylations [150, 287] . Thus, while the presence of multiple potential 
glycosylation sites is maintained, the number and type varies in a cell- and species-
dependent manner.  
Physically, the gain or loss of these glycosylation sites may have a significant 
impact on the size or shape of the mature CD24 peptide. O-linked glycans may contribute 
up to 2.5Å to total protein length [294]. Thus, mouse CD24 would be predicted to extend 
at least 10Å beyond the plasma membrane. The presence of significantly more O-linked 
glycosylation sites in the human sequence suggests that it may be held in a more rigid 
conformation and extend even further from the cell surface. The evolution of the 
conserved glycosylation sites in CD24 suggests that the function of the protein is 
critically dependent on its status as a glycophosphoprotein, with additional flexibility 
depending on the nature of the individual glycosylations [295].  
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Overall, this analysis has clearly shown that CD24 evolution predates the 
divergence between birds, reptiles and mammals, and is conserved across the placental 
mammals. Also, the CD24 protein exists in an intrinsically disordered state and that the 
most evolutionarily constrained regions are related to sites of N- and O-linked 
glycosylation, which mediate CD24-ligand interactions and possibly affect the protein 
structure.  
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Chapter 4 The effect of intrinsic factors on breast cancer progression 
Preliminary data from Dr. Christian’s lab suggested a potential link between Ras 
and CD24 gene expression [296]. Moreover, previous studies have shown that activation 
of oncogenic Ras in BC cells leads to generation of CD24-/CD44+ stem-like cells from 
CD24+/CD44low cells [85]. Despite evidence that overexpression of oncogenic Ras can 
repress CD24 surface expression [85], the mechanism for this regulation of CD24 is not 
known. Here, I examined the regulation of CD24 mRNA and protein levels, as well as 
promoter activity in a model of oncogenic Ras activation and in BC cells with oncogenic 
Ras activation. To analyze the regulation of CD24 expression by oncogenic Ras, I used a 
model system in which constitutively active H-Ras, containing a G12 to V12 mutation 
(RasV12), was stably expressed in the mouse embryonic fibroblast NIH/3T3 cell line 
[297]. To narrow down the downstream regulators of Ras, I used Ras effector mutants 
that constitutively activate either Raf or PI3K or Ral-GDS pathways. I examined the 
pathways regulated by Ras to show that either the PI3K or Raf pathways can repress 
CD24 expression. Surprisingly, inhibition of Raf but not MEK or PI3K significantly 
increased CD24 surface expression. Finally, to determine if there is a similar effect in BC 
cells, I performed a meta-analysis and selected MDA-MB-231 cells that have an inverse 
relation between Ras pathway genes and CD24 to further determine the effect of Raf on 
CD24 surface expression.  
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4.1 Regulation of the BCSC marker CD24 by Ras pathway in a model system 
4.1.1 RasV12 down regulates CD24 mRNA and surface protein expression.  
Initially, the level of CD24 mRNA expression in NIH/3T3 cells stably transfected 
with empty vector (control cells) or containing the constitutively active Ras gene was 
analyzed by RT-PCR and RT-qPCR (Fig 4.1A-B). I observed a clear suppression of 
CD24 mRNA expression (Fig 4.1A) with more than 1000-fold decrease in RasV12 cells 
compared to Babe cells (Fig 4.1B).  
 Similarly, analysis of CD24 surface protein by flow cytometry showed a 
statistically significant reduction in the percentage of CD24+ cells in RasV12 population 
compared to control cells (Fig 4.1C-D). Therefore, I conclude that the reduction of 
expression is due to the majority of RasV12 cells losing CD24 expression entirely. 
Together, these data show that constitutively active Ras significantly downregulates 
CD24 at both the mRNA and surface protein expression levels. Residual levels of CD24 
are due to a small portion of the population retaining surface expression.  
4.1.2 Ras-mediated repression of CD24 at the level of the promoter.   
I next analyzed the activity of the CD24 promoter region comprising the 688 
nucleotides upstream of the TSS (p688) [162]. I found that this region is active in both 
RasV12 and control cells compared to the promoterless control (Fig 4.2A). However, the 
activity was reduced in RasV12 cells compared to control cells. To determine if this 
difference was statistically significant, I analyzed the relative activity in RasV12 versus  
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Figure 4.1: Oncogenic Ras downregulates CD24 expression in NIH/3T3 cells: 
CD24 mRNA expression in vector control (Control) and RasV12 cells was determined by 
(A) RT-PCR and (B) RT-qPCR. RPLP0 was used as the loading and normalization 
control. CD24 mRNA levels shown as mean ± s.e.m. (C) Surface CD24 protein was 
determined by flow cytometry in Control and RasV12 cells. One representative histogram 
of isotype (Iso) and CD24-stained cells is shown. (D) Quantification of CD24 surface 
protein expression as mean ± s.e.m percentage of CD24+ cells. Significance was 
determined by Student’s t-test, n=3, **P<0.01, ***P<0.001. 
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Figure 4.2: RasV12 represses CD24 promoter activity: 
(A, C) Relative promoter activity in vector control and RasV12 is shown compared to 
promoterless vector (pGL4.17). Schematic diagram of promoter deletion constructs are 
shown on the left. Promoter length is indicated by the position upstream of the TSS. (B, 
D) Relative promoter activity in RasV12/Control cells for each reporter construct. 
Significant differences were determined by one-way ANOVA with Tukey Honest 
Significant Difference post-hoc analysis, n=3, -P<0.1 (not significant), *P<0.05, 
***P<0.001, all data are shown as mean ± s.e.m. (E) Schematic diagram showing CD24 
gene structure and the presence of E- box elements 1 and 2 on the repressed region of 
CD24 promoter. E-1-E-box1 and E-2 – E-box2 
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control cells in comparison to the promoterless vector, which represents basal activity 
levels in the two cell types (Fig 4.2B). I found that there was a significant repression of 
the promoter activity in the RasV12 cells. To further narrow down the responsive region, 
I analyzed a series of CD24 promoter deletion mutants (Fig 4.2A-B). I found the relative 
promoter activity in RasV12 versus control cells increased in each deletion mutant 
compared to the full promoter. This increase in p469 promoter region (-469 to -1) activity 
was modest and was not significantly different from control. The relative promoter 
activity in p357 promoter region (-357 to -1) reached significance and was further 
increased when the promoter included only the region from -168 to -1 from the TSS 
(p168). Therefore, both the 112 bp region from -469 to -357 and the 189 bp region from -
357 to -168 contain repressive elements that are regulated by RasV12. However, the 
sequence within -357 to -168 promoter region appears to contribute more to the 
suppression of CD24 than the sequence within the -469 to -357 region. 
I have analyzed the repressive elements for the transcription factors that might 
bind and regulate CD24 transcription. The bHLH proteins bind to enhancer- box (E-box) 
elements that have the consensus sequence CANNTG [298]. TWIST family, bHLH TFs 
regulate CD24 expression, where TWIST1 downregulates CD24 transcription and 
TWIST2 upregulates CD24 transcription [159, 160]. There are two E-box elements, E-
box 1 and E-box 2 on the p688 promoter region of CD24 in between -357 to -168 region 
and -469 to -357 region, respectively (Fig 4.2E). However, promoter analysis of mutated 
E-box elements did not relieve the CD24 promoter repression by Ras pathway (Fig 4.2C-
D). Using JASPAR- a database of TF binding profiles [299], I identified 45 putative TF 
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binding sites located in regions that are repressed by oncogenic Ras. I further narrowed 
down the TF binding sites based on the preliminary microarray data where the genes 
were regulated in presence and absence of U0126 in RasV12 cells [296]. I also performed 
a literature review and found that SPIB, FOXP1, FOXO3, Sox5, and Sox17 TFs might 
play a role in repressing the CD24 promoter (Table 4.1). Overall, these data show that E-
box elements do not repress CD24 promoter activity in response to oncogenic Ras, and 
that further analysis of other TFs is necessary to fully elucidate this interaction. 
4.1.3 Activation of either the Raf or the PI3K pathway is sufficient to downregulate 
CD24 expression.  
Since I observed that CD24 mRNA and protein expression are downregulated by 
Ras, I next asked which pathways downstream of Ras are sufficient to suppress CD24 
expression. Ras activates three major pathways, the Raf, RalGDS, and PI3K pathways, 
all of which contribute to the fully transformed phenotype of cancer cells [300]. I made 
use of NIH/3T3 cells expressing the Ras effector mutants RasV12G37, RasV12S35 and 
RasV12C40 [301–303], in which only one pathway is activated. Specifically, 
RasV12G37 activates only RalGDS but not PI3K or Raf. In a similar manner, 
RasV12S35 selectively activates the Raf pathway, and RasV12C40 selectively activates 
the PI3K pathway. 
I observed a downregulation in CD24 mRNA expression in RasV12S35 and 
RasV12C40 effector mutants compared to control cells by RT-PCR (Fig 4.3 A). In   
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Table 4.1: List of predicted transcription factors and their role in regulation of 
genes. 
Transcription 
factor 
Family Consensus 
sequence 
DNA 
binding 
site 
uptream 
of 3'TSS 
Relationship with 
Ras pathway 
Role Ref 
SPIB SPI 
subclass 
of ETS 
family 
GGAA/T 347 - 341 ERK1 
phosphorylates 
SPIB which 
decreases its 
stability, which 
inactivates 
transcription by 
SPIB 
Activator [304, 
305] 
FOXP1 P 
subclass 
of 
forkhead 
family 
TATTT(G/
A)T 
349 - 336 PI3K/Akt 
increases FOXP1 
activity via 
p70s6k 
Repressor [306] 
FOXO3 O 
subclass 
of 
forkhead 
family 
GTAAAC
A (FOXO 
consensus 
sequence) 
345 - 335 PI3K/Akt 
inactivates FOXO 
proteins by 
phosphorylation 
further decreasing 
DNA binding 
ability of FOXO 
proteins 
Activator [307] 
Sox5 SRY 
related 
HMG-
box 
related 
family 
AACAAT 342 - 336 Inhibition of MEK 
by U0126 
increased Sox5 
mRNA expression 
Activator [296] 
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Sox17 SRY 
related 
HMG-
box 
related 
family 
(A/T)(A/T)
CAA(A/T) 
341 - 333 Inhibition of MEK 
by U0126 
increased Sox17 
mRNA expression 
Activator [296] 
aAbbreviations: FOXP1-forkhead box P1, FOXO3 – forkhead box O3, SOX – SRY 
related HMG box 
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Figure 4.3: The Raf and PI3K pathways downregulate CD24 mRNA expression 
while the Raf pathway is primarily responsible for downregulation of CD24 surface 
protein expression: 
 (A) CD24 mRNA expression in Control, RasV12, RasV12G37, RasV12S35 and 
RasV12C40 cells was determined by RT-PCR. H-Ras mRNA expression was used to 
verify expression of ectopic Ras. RPLP0 was used as the loading control. (B) RT-qPCR 
was used to quantify CD24 mRNA expression with RPLP0 used as the normalization 
control. (C) Surface CD24 protein was determined by flow cytometry. One representative 
histogram of isotype (Iso) and CD24-stained cells is shown. (D) Quantification of CD24 
surface protein expression as mean ± s.e.m percentage of CD24+ cells. Significance was 
determined by one way ANOVA with Tukey Honest Significant Difference analysis, 
n=4, different lower case letters indicating different groups at P<0.01. 
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contrast, the RasV12G37 cells had a similar level of CD24 mRNA expression as the 
control cells (Fig 4.3A). Quantitative analysis of CD24 mRNA by RT-qPCR revealed the 
change in CD24 mRNA expression levels in RasV12S35 and RasV12C40 cells to be 
statistically significant when compared to control cells and RasV12G37 but not different 
from RasV12 cells (Fig 4.3B). 
I then determined if CD24 surface protein expression was also affected in Ras 
effector mutant cells (Fig 4.3C). I found that there was a significant and substantial 
reduction in the percentage of cells expressing CD24 surface protein in RasV12 and 
RasV12S35 cells (Fig 4.3D). RasV12G37 and RasV12C40 expression had an 
intermediate effect on reducing the percentage of cells expressing CD24, compared to 
control cells. Therefore, activation of the Raf kinase pathway, the PI3K pathway, or the 
RalGDS pathway downstream of Ras are sufficient to decrease the CD24+ population. 
However, activation of the Raf pathway was sufficient to decrease the CD24+ population 
to the same low level as RasV12 suggesting that the Raf pathway is the major regulator 
of CD24 expression in these cells. Moreover, Raf and PI3K could decrease both CD24 
mRNA and surface expression while RalGDS only partially affected surface expression. 
4.1.4 Inhibition of MEK or PI3K does not fully restore CD24 mRNA expression.  
Since we observed that both CD24 mRNA and protein were significantly and 
substantially downregulated by the Raf and PI3K pathways, I next determined if 
inhibition of either or both of these pathways could restore CD24 expression in RasV12 
cells at the mRNA level. The major downstream effectors of Raf are the MEK1/2 kinases  
102 
 
[308], which can be inhibited specifically with the chemical inhibitor U0126 [270]. PI3K 
can be inhibited directly using LY294002 [270, 271]. Considering the duration of 
transcription and translation, I incubated the cells with inhibitors for 16 h for mRNA 
expression and for 24 h for protein expression. I evaluated the inhibition of 
Raf/MEK/ERK and PI3K/Akt pathways using western blot analysis of phosphorylated 
ERK (P-ERK) and phosphorylated Akt (P-Akt), respectively (Fig 4.4A). I found that 
RasV12 cells treated with U0126 had reduced phosphorylation of ERK with no effect on 
Akt phosphorylation. Similarly, RasV12 cells treated with LY294002 had reduced 
phosphorylation of Akt with no effect on ERK phosphorylation. Treatment with both 
U0126 and LY294002 inhibited phosphorylation of both ERK and Akt. I found that 
treatment of RasV12 cells with U0126 had a modest, but significant 6-fold increase in 
CD24 mRNA expression (Fig 4.4B-C). Surprisingly, treatment with LY294002 alone or 
in combination with U0126 suppressed CD24 mRNA expression to below the levels seen 
in RasV12 cells (Fig 4.4B-C). 
Since U0126 modestly increased CD24 mRNA levels, I next determined the 
effect of U0126 on CD24 surface protein in control cells and RasV12 cells. 
Unexpectedly, I found that U0126 increased the percentage of CD24+ cells in the control 
cell population (Fig 4.4D-E). In contrast, there was a modest but not statistically 
significant increase in the percentage of CD24+ RasV12 cells treated with U0126 (Fig 
4.4D-E). Therefore, even though the Raf pathway is sufficient to decrease CD24 mRNA 
and protein, inhibition of oncogenic Raf/MEK signaling does not restore CD24 
expression to the level of control cells at the mRNA or protein level.  
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Figure 4.4: Inhibition of the Raf/MEK/ERK pathway is sufficient to partially restore 
CD24 mRNA but not protein expression in RasV12 cells: 
 (A-C) RasV12 cells were treated for 16 h with DMSO (D), or U0126 (U) and/or 
LY294002 (LY). (A) Western blot analysis was performed to detect phosphorylated ERK 
(P-ERK), and phosphorylated Akt (P-Akt). Total ERK and total Akt were used as loading 
controls. Molecular mass standards are shown in the right of each image. One 
representative experiment from three replicates is shown. CD24 mRNA expression in 
Control and RasV12 cells was determined by (B) RT-PCR and (C) RT-qPCR. RPLP0 was 
used as the loading and normalization control. Significance was determined by one-way 
ANOVA with Tukey Honest Significant Difference post-hoc analysis, *P<0.05. (D) 
Surface CD24 protein was determined by flow cytometry with Control or RasV12 cells 
treated for 24 h as above. One representative histogram of isotype (Iso) and CD24-stained 
cells is shown. (E) Quantification of CD24 surface protein expression as mean ± s.e.m 
percentage of CD24+ cells. Significance was determined by Student’s t-test, n=4, - P<0.1, 
**P<0.01. 
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4.1.5 Inhibition of Raf partially restores CD24 cell surface protein expression in cells 
expressing oncogenic Ras but not control cells.  
Since I observed that inhibition of MEK partially restored CD24 mRNA with no 
significant effect on protein levels, I next determined if inhibition of Raf directly could 
restore CD24 expression levels. Raf is the major downstream target of Ras and can be 
directly inhibited by sorafenib, which does not inhibit MEK or ERK [309]. I evaluated 
the inhibition of Raf/MEK/ERK pathway by sorafenib at different concentrations using 
western blot analysis of phosphorylated ERK (P-ERK) and phosphorylated Akt (P-Akt) 
as measures of efficacy and specificity (Fig 4.5A). I found that sorafenib reduced ERK 
phosphorylation in RasV12 cells at all concentrations examined. I also found that both 
phosphorylated and total Akt was reduced with 10 and 20 M sorafenib. Sorafenib is 
known to inhibit additional kinases such as EGFR, PDGFR, c-Kit and FLT-3 [309, 310], 
therefore, it is not surprising to observe inhibition of additional pathways with this 
inhibitor. However, I found that treatment of RasV12 cells with sorafenib had no effect 
on CD24 mRNA expression (Fig 4.5B-C). 
I next determined the effect of Raf inhibition by sorafenib on CD24 surface 
protein in control cells and RasV12 cells. We found that treatment with 20 M but not 5 
or 10 M sorafenib significantly increased the percentage of CD24+ cells within the 
RasV12 cell population (Fig 4.5D-E). In contrast to MEK inhibition, there was no change 
in the percentage of CD24+ cells in the control cells after treatment with sorafenib (Fig 
4.5D-E). Therefore, inhibition of Raf significantly increases the proportion of  
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Figure 4.5: Inhibition of Raf is sufficient to increase CD24 cell surface protein but 
not mRNA expression in RasV12 cells: 
 (A-C) Rasv12 cells were treated for 16 h with DMSO (D) or 5µM, 10µM and 20µM 
sorafenib (S). (A) Western blot analysis was performed as in figure 4.4. One 
representative experiment from three replicates is shown. CD24 mRNA expression in 
Control and RasV12 was determined by (B) RT-PCR and (C) RT-qPCR as in figure 4.4. 
Significance was determined by one-way ANOVA with Tukey Honest Significant 
Difference post-hoc analysis, n=3. (D) Surface CD24 protein was determined by flow 
cytometry with Control and RasV12 treated for 24 h as above. One representative 
histogram of isotype (Iso) and CD24-stained cells is shown. (D) Quantification of CD24 
surface protein expression as mean ± s.e.m percentage of CD24+ cells. Significance was 
determined by one way ANOVA with Tukey Honest Significant Difference analysis, 
n=3, different lower case letters indicate different groups at P<0.001. 
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CD24+ cells in the absence of changes at mRNA level, but only in cells expressing 
oncogenic Ras. 
4.1.6 Inhibition of PI3K does not synergize with Raf inhibition to affect CD24 
mRNA or surface protein expression.  
I next determined if inhibition of both PI3K and Raf together could further restore 
CD24 expression in RasV12 cells at the mRNA and surface protein levels. I evaluated the 
inhibition of PI3K/Akt and Raf/MEK/ERK pathways using western blot analysis of 
phosphorylated ERK (P-ERK) and phosphorylated Akt (P-Akt), respectively, as 
previously discussed (see section 4.1.4) (Fig 4.6A). Similar to  previous observations, I 
found that treatment of RasV12 with LY294002 reduced phosphorylation of Akt with no 
effect on phosphorylation of ERK. Treatment with both LY294002 and sorafenib 
inhibited phosphorylation of both ERK and Akt, as expected. I found that treatment with 
both LY294002 and sorafenib did not increase CD24 mRNA expression (Fig 4.6B-C). 
I found that treatment of RasV12 cells with LY294002 alone did not affect the 
percentage of CD24+ cells in either control or RasV12 cells (Fig 4.6D-E). Moreover, 
addition of LY294002 did not affect the sorafenib-induced increase in the percentage of 
CD24+ cells (Fig 4.6E). Together, these data indicate that even though activation of 
either the PI3K or Raf pathway is sufficient to decrease CD24 mRNA and protein 
expression, inhibition of both PI3K and Raf together is not sufficient to restore CD24 
surface protein or mRNA expression. 
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Figure 4.6: Inhibition of PI3K did not alter the Raf-mediated inhibition of CD24 
expression: 
 (A-C) Rasv12 cells were treated for 16 h with DMSO (D), 100µM LY294002 (LY) 
and/or 10µM or 20µM sorafenib (S/Sor) with LY. (A) Western blot analysis was 
performed as in figure 4.4. One representative experiment from three replicates is shown. 
CD24 mRNA expression in Control and RasV12 was determined by (B) RT-PCR and (C) 
RT-qPCR as in figure 4.4. Significance was determined by one way ANOVA with Tukey 
Honest Significant Difference post-hoc analysis, n=3, a,bP<0.01.  (D) Surface CD24 
protein was determined by flow cytometry with Control and RasV12 for 24 h as above. 
One representative histogram of isotype (Iso) and CD24-stained cells is shown. (D) 
Quantification of CD24 surface protein expression as mean ± s.e.m percentage of CD24+ 
cells. Significance was determined by one way ANOVA with Tukey Honest Significant 
Difference analysis, n=3, different lower case letters indicating different groups at 
P<0.001. 
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4.2 Regulation of BCSC marker, CD24 by Ras pathway in BC cell lines 
4.2.1 Relationship between CD24 and Ras pathway gene expression in human breast 
cancer.  
To select cell lines that have an inverse relationship between the Ras pathway 
genes and CD24, we analyzed previously published DNA microarray datasets [224, 265–
268] from 9 different BC cells or normal cells (Table 2.1). An inverse relationship was 
confirmed by considering the datasets, where the cells under different conditions showed 
alterations in expression of Ras pathway genes and CD24. Ten of the gene expression 
profiles were obtained using the Affymetrix HG-U133A_2 array, while one used the HG-
U133_plus_2 array (Table 4.2). Both of these platforms share the same strategy of 
interrogating the 3’ region of mRNA transcripts and, therefore, can be compared directly, 
as well as being the most commonly used platform for analyzing whole genome 
expression data from breast cancer cells in the GEO repository [261]. I performed 
unsupervised hierarchical cluster analysis of CD24 along with genes in the three major 
pathways downstream of Ras, and the different Ras isoforms (Fig 4.7). All of the 
probesets representing all the isoforms of each gene in a gene family (i.e. all Ras 
isoforms) were evaluated for their presence in the same cluster as the CD24 probeset in 
each cell type/treatment (Fig 4.7). 
The cells analyzed were separated into three broad categories: 1) cells expressing 
ER, PR or HER-2, 2) TNBC cells, and 3) normal or immortalized cells [9, 311, 312].   
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Table 4.2: The total number probesets representing the Ras pathway genes and CD24 
from each platform.  
Gene/Gene family Number of probesets 
HG-U133A_2 HG-U133_plus_2 
CD24 6 6 
Ras 10 15 
Raf 3 7 
MAPK1 5 6 
Ral/Ral GDS 2 7 
PIK3C 12 27 
PIK3R 10 12 
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Figure 4.7: Hierarchical cluster analysis of Ras pathway genes and CD24 expression 
in ER/PR or HER2 positive, TNBC and normal/immortalized cells. Analysis of gene 
expression by unsupervised hierarchical clustering by gene and sample of (A1-4) ER/PR 
or HER2 positive, (B1-4) TNBC and (C1-3) normal/immortalized cells or cell lines. 
Clusters containing any CD24 probeset are highlighted in pink. Gene expression levels, 
normalized to median, are coloured by expression as indicated. High gene expression is 
shown in red and low expression is shown in red. 
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Overall, based on the cluster that have similar expression with CD24, I found that ER, PR 
and HER-2 expressing cells tended to have the highest association of CD24 with Ras 
pathway genes, followed by TNBC and then normal/immortalized cells (Fig 4.8).  
HCC1954 HER2-positive breast cancer cells sorted on the basis of CD24, CD44 
and ALDH protein expression, demonstrated the highest association of Ras pathway 
genes with CD24, with all of these genes clustering with CD24 (Fig 4.8). Similarly, ER-
positive MCF7 cells sorted on the basis of CD24, CD44 and ALDH protein expression, 
showed a highly positive correlation with Ras pathway genes with all gene families, 
except MAPK1, clustering with CD24 (Fig 4.8A).  
In addition, with the exception of the CD24-CD44+ALDH- population, CD24 
expression was generally high in MCF7 cells (Fig 4.7). However, when ER-positive 
MCF7 cells were treated with inhibitors or activators in a way that upregulates the Ras 
pathway genes, the association with CD24 was substantially reduced. In the case where 
MCF7 cells were treated with siRNA against ERK1 and ERK2 individually, followed by 
treatment with estradiol (E2), there were few Ras related genes that clustered with CD24, 
with only genes in the Ral/RalGDS, PIK3C and PIK3R gene families represented (Fig 
4.7A3). However, knockdown of ERK1 with or without E2 treatment dramatically altered 
the expression profiles of the Ras pathway genes and CD24, with the combination 
resulting in an obvious decrease in CD24 expression levels and increase in Ras pathway 
gene expression (Fig 4.7A3). Similarly, MCF7 cells treated with insulin-like growth 
factor (IGF) upregulate Ras pathway genes resulting in an overall low percentage of Ras 
pathway genes clustering with CD24, with only Ras, Ral/RalGDS, and PIK3R gene   
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Figure 4.8: Summary of meta-analysis showing clustering of Ras pathway gene 
probesets with CD24 from DNA microarray datasets obtained from ER/PR or 
HER2 positive, TNBC and normal/immortalized cells. (A) The percentage of 
probesets representing Ras pathway associated genes that clustered with CD24 in ER/PR 
or HER2 positive (HCC1954, MCF7), TNBC (SUM149, SUM159, MDA-MB-231 and 
MC1), normal/immortalized (MCF-10F, MCF-10A and patient (sorted cells)) cell lines is 
shown. (B) The average percentage of Ras pathway genes clustered with CD24 genes in 
ER/PR or HER2 pos, TNBC and normal/immortalized cells is shown.  
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families clustered with CD24 (Fig 4.8). In the untreated cells, over half of the Ras 
pathway genes had high expression levels and were similar to CD24, but upon treatment, 
CD24 levels were substantially reduced along with many, but not all, of the Ras pathway 
genes reduced as well (Fig 4.7A4). 
Non-tumorigenic cells, including MCF-10F, MCF-10A and normal patient cells, 
sorted by CD44, CD24 and ALDH, gene expression showed the strongest inverse 
relationship between Ras pathway genes and CD24, with only four out of 6 gene families 
clustering with CD24 (Fig 4.8). Ral/RalGDS showed the highest direct association with 
CD24 in these cells but neither MAPK1 nor Raf showed any association with CD24.  
 Cells with the TNBC phenotype (MC1 cells derived from primary xenografts, 
SUM149, SUM159, and MDA-MB-231) showed an intermediate association with Ras 
pathway genes and CD24 compared to that seen with immortalized/normal cells or the 
ER/PR and HER-2 positive cells. In addition, all but the MAPK1 gene family never 
clustered with CD24 in TNBC group. Interestingly, in MDA-MB-231 cells that were 
treated with siRNA against Pin1, which is a protein that cooperates with Ras [313], a 
cluster of Ras pathway genes was downregulated while CD24 expression increased, 
suggesting that alterations in the Ras pathway can alter CD24 expression in this cell line. 
In a similar manner, when MDA-MB-231 cells treated with siRNA against p53, 
upregulation in Ras-related genes such as BRAF, MAPK1 and downregulation in CD24 
expression was observed (Fig 4.7 B3). 
In summary, this meta-analysis showed that the untreated ER-positive (MCF7) 
and HER-2 positive (HCC1954) cells had, on average, a positive association of Ras 
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pathway genes with CD24, while the normal and TNBC cells had fewer genes and fewer 
different gene families associating with CD24 (Fig 4.8B). Of note, in TNBC and normal 
cells, MAPK1 (ERK2) never clustered with CD24, and Ral/RalGDS clustered the most 
often with CD24. In addition, these data suggest that TNBC cells, sorted by BCSC 
markers, are more similar to normal cells than ER/PR or HER-2 positive cells, with 
respect to this set of genes.  
4.2.2 Inhibition of Ras/MEK/ERK increases CD24 mRNA but not protein 
expression in MDA-MB-231 CD24- breast cancer cells.  
MDA-MB-231 cells are TNBC and considered to model BCSC since the majority 
of the cells are CD44+CD24-ALDH+ [79]. In addition, K-Ras is constitutively active in 
these cells [314, 315]. The above meta-analysis revealed an inverse correlation between 
CD24 and Ras pathway genes in MDA-MB-231 cells, which was enhanced by the lack of 
the Ras pathway associated gene, Pin1. Therefore, I reasoned that this cell line may 
respond to manipulations of the Ras pathway by altering CD24 levels. I first confirmed 
that, in comparison with MCF7 BC cells, MDA-MB-231 have a low level of CD24 
mRNA expression (Fig 4.9A). To determine if inhibition of the Ras/MEK/ERK pathway 
was sufficient to increase CD24 expression, I treated MDA-MB-231 cells with the MEK 
inhibitor U0126 and analyzed CD24 mRNA expression (Fig 4.9B, C). I found that CD24 
mRNA expression increased in response to inhibition of the Ras/MEK/ERK pathway, 
which was statistically significant when analyzed by RT-qPCR (Fig 4.9C). This suggests  
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Figure 4.9: Regulation of CD24 mRNA but not protein by inhibition of the 
Ras/MEK pathway in MDA-MB-231 breast cancer cells. (A) CD24 mRNA expression 
in MCF-7 and MDA-MB-231 breast cancer cell lines was determined by RT-PCR. (B) 
MDA-MB-231 cells were treated for 24 h with U0126 or the DMSO as the vehicle 
control and then CD24 mRNA levels determined by RT-PCR and (C) qRT-PCR. GAPDH 
was used as the loading control. Significance was determined by Student’s T-test, n=4, 
*P<0.05. Mean ± s.e.m. is shown. (D) Surface CD24 protein levels were determined by 
FACS on MCF7 cells and MDA-MB-231 with or without treatment with U0126 for 24 h. 
One representative experiment of three replicates is shown.  
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that the Ras/MEK/ERK pathway actively suppresses CD24 mRNA expression in these 
cells. 
 I then analyzed the level of CD24 surface protein to determine if the increase in 
CD24 mRNA translated to increases in CD24 surface protein. Using flow cytometry, I 
observed that inhibition Ras/MEK/ERK was not sufficient to upregulate CD24 protein on 
the cell surface (Fig 4.9D). Therefore, this suggests that similar to RasV12 cells, cancer 
cells continue to suppress CD24 surface expression via other pathways or mechanisms. 
4.2.3 Inhibition of Raf does not restore CD24 cell surface protein expression in 
breast cancer cells with oncogenic Ras. 
Since U0126 modestly increased CD24 mRNA levels in MDA-MB-231 BC cells 
but had no effect on CD24 surface protein expression, which is similar to RasV12 cells, I 
next determined if inhibition of Raf could restore CD24 surface protein expression as 
observed in RasV12 cells. I examined an additional BC cell line, SUM159 which also has 
constitutively active Ras and a high proportion of BCSC population [316]. T47D and 
MCF7 BC cell lines were used as positive controls for CD24. I evaluated the inhibition of 
Raf/MEK/ERK pathway by sorafenib for 24h as previously discussed using western blot 
analysis (see section 4.1.4) (Fig 4.10A). Although the sensitivity to sorafenib among 
different cell lines varied, I found that sorafenib reduced ERK phosphorylation in MDA-
MB-231, SUM159, MCF7, and T47D BC cells at all concentrations examined, while Akt 
phosphorylation varied across the cell lines. In MCF7 and SUM159 BC cells sorafenib 
reduced Akt phosphorylation at all concentrations. In contrast, sorafenib treatment   
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Figure 4.10: Regulation of CD24 protein by inhibition of the Ras/Raf pathway in 
T47D, MCF7, MDA-MB-231 and SUM159 breast cancer cells. T47D, MCF7, MDA-
MB-231 and SUM159 BC cells were treated for 24 h with DMSO (D) or 5µM, 10µM 
and 20µM sorafenib. (A) Western blot analysis was performed to detect phosphorylated 
ERK (P-ERK), and phosphorylated Akt (P-Akt). Total ERK and total Akt were used as 
loading controls. Molecular mass standards are shown in the right of each image. One 
representative experiment from two replicates is shown. (B) Surface CD24 protein was 
determined by flow cytometry with Controls, T47D and MCF7 or MDA-MB-231 and 
SUM159 BC cells treated as above. One representative histogram of isotype (Iso) (dotted 
line) and CD24-stained cells is shown. n=2.  
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increased Akt phosphorylation in T47D BC cells. However, MDA-MB-231 cells have 
low or no activation of Akt even in control samples [317, 318] (Fig 4.10A).  
I determined the effect of Raf inhibition by sorafenib on CD24 surface protein in 
MDA-MB-231, SUM159, MCF7 and T47D cells. I found that there was no change in the 
percentage of CD24+ cells in the MDA-MB-231 and SUM159 BC cells after treatment 
with sorafenib (Fig 4.10B). Therefore, inhibition of Raf significantly increases the 
proportion of CD24+ cells exclusively in model systems that have constitutive activation 
of oncogenic Ras human BC cells must have additional mutations that regulate CD24 
gene expression. 
4.3 Discussion 
Here, I have demonstrated that expression of oncogenic Ras is sufficient to 
directly downregulate the expression of CD24 at the mRNA and protein levels, as well as 
repress promoter activity in model systems. In addition, activation of either the Raf or 
PI3K pathway is sufficient to downregulate CD24 expression at both the mRNA and 
protein levels (Fig 4.11). Surprisingly, inhibition of the Raf pathway, at the level of MEK 
or Raf, or the PI3K pathway, at the level of PI3K, either separately or together, was not 
sufficient to fully restore CD24 expression in the model system. However, inhibition of 
Raf directly was able to partially restore CD24 surface protein expression without 
affecting mRNA levels. Moreover, I have shown that cell lines with high ER/PR or HER-
2 expression tend to have a positive association between CD24 and Ras pathway genes, 
while normal or TNBC cells have an inverse correlation of Ras pathway gene and CD24.   
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Figure 4.11: Schematic representation of the regulation of CD24 by Ras/Raf and 
Ras/PI3K pathways. Rectangles represent proteins and ovals represent lipids and second 
messengers. Protein activation is indicated by solid arrows and inhibition indicated by 
solid lines with blunt ends. Potential mechanisms for cross-talk are shown in grey. The 
effect of U0126 and LY294002 on MEK and PI3K and on CD24 transcription is indicated 
by dashed lines and dash dot dash lines, respectively. The effect of sorafenib on Raf and 
on CD24 surface protein expression is indicated by dotted lines. The CD24 promoter is 
indicated with a solid line flanked by genomic DNA depicted with a dotted line. The 
transcription start site is indicated by a bent arrow. Abbreviations not in the main text: 
PLC-, phospholipase C- ; PIP3, phosphotidylinositol-3,4,5-trisphosphate; DAG, 
diacylglycerol; PKC, protein kinase C; PAK, p21-activated kinase; Cdc42, cell division 
cycle 42. 
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Interestingly, inhibition of downstream targets of Ras was not sufficient to increase 
CD24+ cells in TNBC population. Therefore, oncogenic Ras uses additional mechanisms 
to regulate CD24 surface protein expression in both model system and TNBC cell lines. 
Experimental analysis of the CD24 promoter region revealed that repression of 
CD24 promoter activity by oncogenic Ras was primarily mediated by the 189 bp region 
between -168 and -357. In addition, a 112 bp region between -357 and -469 also appears 
to contribute to this repression. Therefore, I have identified a novel negative regulatory 
region between -168 and -357 that may act independently or in cooperation with 
additional elements between -357 and -469 to regulate CD24 transcription in response to 
oncogenic Ras.  
Computational analysis of the 112 bp region revealed more than 300 potential 
transcription factor binding sites, including 5 sites that can bind TWIST transcription 
factors. However, deletion of these sites did not affect the repression of CD24 promoter 
by Ras (Fig 4.2C-D). Moreover, 5 TF binding sites on the CD24 promoter region were 
predicted by JASPAR database  and are potentially regulated by Ras directly or indirectly 
(Table 4.1). While regulation of the CD24 promoter by methylation has been reported in 
diseased conjunctiva [165] and glioblastoma cell lines [164], there was no evidence of 
promoter methylation of CD24 in breast cancer cell lines or in patient tumors in previous 
study [7]. Therefore, further work is necessary to validate TFs predicted from 
computational analysis and the other 189 bp region in order to identify the precise 
regulatory mechanism used by Ras to repress CD24 transcription. 
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 To narrow down which of the Ras-activated pathways represses CD24 expression 
I made use of the Ras effector mutants and found that activation of either the PI3K or the 
Raf pathway is sufficient to decrease CD24 mRNA expression but the Raf pathway is the 
major repressor of CD24 expression at both the mRNA and protein levels. Unexpectedly, 
when I performed the complementary loss-of-function experiments using either the MEK 
inhibitor U0126 or the Raf inhibitor sorafenib in the presence or absence of the PI3K 
inhibitor LY294002, we were unable to restore CD24 mRNA expression to the level of 
the control cells. Of note, U0126 treatment partially restored CD24 mRNA levels in 
RasV12 cells, suggesting that this partial restoration is common to our model mouse cell 
line. Treatment with U0126 caused a 13-fold increase in RasV12, which is still 100-fold 
lower than the mRNA levels present in control cells, and therefore may be responsible for 
the modest but not statistically significant increase in CD24 surface expression. In 
contrast, sorafenib treatment did not alter CD24 mRNA levels. Inhibition of PI3K alone 
did not alter CD24 mRNA levels but in combination with MEK inhibition prevented the 
U0126-mediated increase in CD24 mRNA expression. Thus, these data suggest that the 
inhibition of the PI3K pathway could potentially activate a repressor or inhibit an 
activator of CD24 mRNA expression to block the effects of U0126 treatment. Consistent 
with this hypothesis, significant cross-talk between the PI3K and Raf pathways has been 
shown, including the ability of Akt to inhibit Raf. As we did not observe an increase in 
ERK phosphorylation, the possible relief of Akt-mediated inhibition of Raf did not 
override the U0126-mediated block in MEK activation. Thus, inhibition of the PI3K 
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pathway may relieve the Akt-mediated inhibition of Raf and promote Raf mediated 
suppression of CD24 (Fig 4.11). 
 Interestingly, sorafenib treatment significantly increased the proportion of CD24+ 
RasV12 cells while U0126 treatment significantly increased CD24+ cells only in the 
control cell population. This suggests that regulation at the level of Raf regulates CD24 
expression in oncogenic conditions, while MEK can regulate CD24 expression in 
response to basal growth conditions. In both situations ERK phosphorylation is equally 
inhibited, therefore. the regulation of CD24 surface expression cannot be downstream of 
ERK activation. Together, these data demonstrate that the regulation of CD24 surface 
protein expression is regulated in a Raf-dependent, MEK-independent manner in model 
system.  
Meta-analysis revealed that Ras pathway genes tended to cluster with CD24 in 
ER/PR and HER-2 positive. In contrast, both TNBC and normal cells had low percentage 
of Ras-associated genes that correlated with CD24. In particular, MAPK1 did not 
correlate with CD24 in any of the TNBC or normal cells. The Ral/RalGDS genes showed 
the highest correlation with CD24 overall, which supports previous observations that the 
Ral pathway can positively regulate CD24 expression [319]. In agreement with these 
data, I found that the activation of Ral pathway was not sufficient to downregulate CD24 
mRNA expression. Overall, this meta-analysis supports the apparent paradox that CD24 
is pro-proliferative in some cancers but anti-proliferative in other cancers [82], and 
supports previous expression profile analysis of breast cancer cells showing that the 
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mRNA expression levels of oncogenic Ras pathway genes is higher in CD24- cells 
isolated from populations of primarily CD24+ cells [320]. 
Next, I found that MDA-MB-231 that carries the oncogenic G13D K-Ras 
mutation [314, 315], and SUM159 cells that carry both H-Ras and PI3CA mutation have 
low CD24 expression. Furthermore, overexpression of oncogenic H-Ras as part of the 
sequential transformation of primary human mammary epithelial cells resulted in the 
downregulation of CD24 surface expression [85]. Therefore, the downregulation of CD24 
expression at the mRNA and surface protein levels in response to oncogene activation  
appears to be common to different oncogenic Ras isoforms but, according to the meta-
analysis, likely restricted to TNBC-like cells.  
Similarly, U0126 treatment did not increase surface expression of CD24 in MDA-
MB-231 cells even though there was a significant 4-fold increase in mRNA expression. 
In contrast, sorafenib treatment Raf inhibition had no effect on CD24+ cells among 
MDA-MB-231 and SUM159 cell populations. These data suggest that downregulation of 
CD24 is dependent on more than Raf or MEK in human BC cells. In BC cells where not 
only Ras but also other oncogenes such as PIK3CA and BRAF and tumor suppressor 
genes such as TP53 and CDKN2A, are mutated [18]. In addition to constitutive activation 
of oncogenes or constitutive suppression of tumor suppressor genes, there is inter 
dependencies of the proteins in these pathways. However, in a recent study it is shown 
that Ras, PI3K, p53, and cell cycle pathways consists of mutually exclusive pairs where 
one alteration is sufficient to functionally alter the other pathways [321]. Furthermore, 
these data suggest that additional pathways remain activated in the presence of the Raf, 
141 
 
MEK, or PI3K inhibition that can continue to repress CD24 expression. For example, as 
depicted in figure 4.11, both p21 protein (Cdc42/Rac)-activated kinase (PAK) and protein 
kinase C (PKC) can positively regulate the Raf/MEK/ERK pathway at multiple levels to 
bypass Raf or MEK inhibition [181, 322, 323]. 
These inhibitor experiments, as well as our observation that there is a reduction in 
CD24 cell surface protein expression but not mRNA expression in RasV12G37 cells, 
strongly suggest that the downregulation of CD24 mRNA and surface expression are not 
mediated by the same mechanisms. Moreover, CD24 has substantial post-translational 
modifications, including protein cleavage, addition of the GPI-anchor, and major O- and 
N-linked glycosylations, that occur prior to surface expression [150]. Thus, the Ras/Raf 
or the Ras/Ral pathways may also regulate post-translational modification or trafficking. 
The interaction of Raf-1 with the actin cytoskeleton has been shown to be necessary for 
efficient activation of MEK/ERK [324], but no Raf-mediated MEK-independent 
regulation of protein trafficking has been reported. On the other hand, Ral is well known 
to regulate vesicle trafficking [180]. While Ral can be activated in a Ras-independent 
manner [325], it is not known if Ral can be activated in a Raf-dependent manner. 
Alternatively, alteration of GPI-anchor biosynthesis by Ras, as previously identified in 
Saccharomyces cerevisiae [326], may be responsible for altering CD24 surface 
expression. Therefore, future work will be necessary to unravel the precise mechanism 
that regulates CD24 surface protein expression by the Ras/Raf pathway. 
 CD24 expression is dynamically regulated throughout the development of B and 
T lymphocytes, dendritic cells, neurons, and adipocytes [272, 281, 327]. Moreover, CD24 
142 
 
expression in some normal cell types is associated with proliferation or differentiation 
[272, 328], while in others it is associated with apoptosis [329]. Therefore, transformation 
of a particular cell type at a particular cell stage may dictate if CD24 promotes or inhibits 
proliferation. Previously, it was found that overexpression of oncogenic H-Ras as the last 
part of the sequential transformation of primary human mammary epithelial cells or in 
immortalized MCF10A cells resulted in an epithelial to mesenchymal transition (EMT) 
concomitant with the downregulation of CD24 surface expression [85]. Here, I have 
found that the expression of oncogenic Ras in mouse embryonic fibroblasts and BC cells, 
which are already mesenchymal, represses CD24 mRNA and protein expression, and 
promoter activity. Therefore, it may be the mesenchymal phenotype that predisposes a 
cell to lose CD24 expression in response to Ras transformation while other cell types will 
gain or retain CD24 expression dependent on their epithelial vs. mesenchymal status. 
Here, I have targeted both Raf/MEK and PI3K/Akt pathways to relieve the CD24 
suppression caused by Ras activation. Unlike RasV12 cells, cancer cells find an 
alternative to downregulate CD24 surface protein expression, even after inhibiting Raf 
with sorafenib. This suggests that cancer cells can alter the signaling pathways which are 
favorable for their survival and proliferation. Moreover, this indicates suppression of 
CD24 expression is important for cancer cells to survive from sorafenib treatment. In the 
future, a more detailed understanding of CD24 regulation by oncogenic Ras is required in 
order to increase CD24 protein expression and manipulate the size of the BCSC 
population to improve therapeutic response of breast cancer patients. This strategy would 
decrease the percentage of BCSC in the tumor and therefore reduce the ability of the 
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tumor to be radiation-resistant or initiate secondary tumor formation. These data clearly 
demonstrate that the oncogenic Ras-mediated suppression of CD24 expression is 
regulated at multiple levels.  
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Chapter 5. The effect of extrinsic factors on breast cancer progression  
Several 2D co-culture studies have shown that adipocytes or medium from 
adipocyte co-cultures enhances BC progression, invasion and migration [61, 132, 208, 
235]. However, the laminin-rich ECM modeled by matrigel can provide additional 
insight into the microenvironment of the normal mammary gland [17, 18]. Adipocytes 
can induce the expression of mesenchymal markers and promote invasion of BC cells in a 
Transwell culture system, suggesting an increase in EMT [12]. However, the role of 
adipocytes in colonization or induction of epithelial phenotype in mesenchymal cells is 
unexplored. Here, I investigated the effects of adipocytes on TNBC progression using a 
novel 3-dimensional (3D) co-culture system, which better mimics the tumor 
microenvironment and models both EMT and MET more accurately than 2D culture 
systems [135, 330]. 
5.1 Adipocytes cause mesenchymal BC cells grown in 3D to adopt more epithelial 
type structures with little effect on epithelial BC cells. 
I first determined if co-culturing adipocytes with the mesenchymal or partly 
mesenchymal cells, MDA-MB-231, Hs578t and SUM159 cells or epithelial MCF7 cells 
grown in 3D cultures affected the structure of the BC cell lines. I found that adipocytes 
significantly increased the number of grape-like, and round/mass-like structures formed 
by MDA-MB-231 and Hs578t cells (Fig 5.1A-B). SUM159 cells have a stellate 
morphology in 2D culture [331] that changes to a mixed morphology in 3D culture with 
more round/grape like structures, as compared to MDA-MB-231 and Hs578t cells for   
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Figure 5.1: Adipocytes alter the characteristic morphology of mesenchymal but not 
epithelial BC cell lines grown in 3D. Representative images of (A) MDA-MB-231 cells, 
(B) Hs578t cells, (C) SUM159 cells, and (D) MCF7 cells grown in the 3D co-culture 
system without adipocytes, with adipocytes, or with adipocyte conditioned medium 
(CM). To the right of each image, the total percentage of structure shapes is shown as 
mean ± SD calculated from 3 biological replicates. Overall significance of the proportion 
of colony shapes between the treatments was determined by 2 analysis, **P<0.01, 
***P<0.001. If significant by 2, differences between the conditions for each shape was 
determined using one-way ANOVA with Tukey HSD post hoc analysis. Different letters 
or symbols represent statistically different groups a,b,cP<0.05 for stellate, 1,2,3P<0.05 for 
grape-like, and α,β,Υ,θP<0.01 for round/mass-like.  
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example. This mixed morphology was minimally affected by co-culture with adipocytes 
(Fig 5.1C). MCF7 cells form a cobblestone-like morphology in 2D culture that changes 
to round/mass-like morphology in 3D culture [332]. I found that adipocytes had no 
significant effect on the morphology of MCF7 cells in the co-culture system (Fig 5.1D).  
I next analyzed if these morphological changes are induced by a secretory 
mediator released by adipocytes cultured with ECM or via a physical interaction with the 
adipocytes. I focused only on cell lines where an adipocyte-induced effect was seen. I 
found that adipocyte CM induced the loss of stellate and the gain of grape-like structures 
in MDA-MB-231 and Hs578t cultures, along with an intermediate and non-significant 
increase in round/mass-like structures (Fig. 5.1A, B). Similar to adipocytes, CM had no 
substantial effect on the specific colony morphology of SUM159 cells in 3D cultures 
(Fig. 5.1C). 
5.2 Adipocytes have a partial effect on expression of mesenchymal to epithelial 
transition markers in MDA-MB-231 and Hs578t cells 
I next assessed the use of IF to specifically detect the expression of EMT protein 
markers in the 3D co-cultures. I examined expression of Claudin-7, ZO-1, and E-
cadherin, which are epithelial markers, and vimentin, a mesenchymal marker in the 
presence and absence of adipocyte co-culture [202].  
As expected, the MDA-MB-231 and Hs578t cells grown in the absence of 
adipocytes had high vimentin and low E-cadherin, ZO-1 and Claudin-7 expression. 
MCF7 cells had high expression of epithelial markers and low expression of vimentin, 
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whereas, SUM159 cells had high E-cadherin, ZO-1, Claudin-7 and vimentin expression 
(Fig 5.2). I observed that adipocytes induced a significant gain in the expression of both 
E-cadherin and Claudin-7 in MDA-MB-231 and Hs578t cells (Fig 5.2A-D). In addition, 
Hs578t showed a significant reduction in vimentin expression (Fig. 5.2C-D). Significant 
changes to ZO-1 were not observed in any of the cell lines when co-cultured with 
adipocytes. EMT markers were not significantly altered in either SUM159 or MCF7 cells 
(Fig 5.2E-H). When cultured with adipocyte CM, no significant changes in EMT 
biomarker expression were observed in any of the cells (Fig 5.2). Together, these data 
suggest that mature adipocytes promote a partial MET in mesenchymal MDA-MB-231 
and Hs578t cells that is not fully recapitulated by secretory mediator. 
5.3 Adipocytes have a partial effect on BC stem cell biomarkers but no effect on 
proliferation markers 
Similarly, I analyzed the effect of adipocytes on the presence of BC stem cells 
(BCSCs) as indicated by CD44high/CD24low expression, biomarkers known to correlate 
with the abundance of BCSCs in cell culture [18]. I found that adipocytes and adipocyte 
CM increased CD24 levels in MDA-MB-231 cells with no change observed in any of the 
other cell lines (Fig 5.3). Thus, mature adipocytes induce the gain of CD24 but this is not 
likely to be associated with the BCSC phenotype. Moreover, the CM-induced increase of 
CD24 expression indicates that a secretory factor promotes this increase.  
I next analyzed the effect of adipocytes on expression of the Ki67 proliferation 
marker. I found that there was no significant change in Ki67 expression levels in any of   
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Figure 5.2: Adipocytes partially enhance MET of mesenchymal BC cells in 3D 
culture with little to no effect on epithelial BC cells. Representative images of (A) 
MDA-MB-231 cells, (C) Hs578t cells, (E) SUM159 cells and (G) MCF7 cells cultured 
with or without adipocytes or CM and co-stained with anti-vimentin, anti-ZO-1, and 
DAPI (left panel), or with anti-E-cadherin, anti-Claudin-7 and DAPI (right panel) (scale 
bar=50µm). The average protein expression in (B) MDA-MB-231 cells, (D) Hs578t cells, 
(F) SUM159 cells and (H) MCF7 from 5 images per replicate from different fields of 
view for the BC cells was normalized to DAPI and analyzed relative to control cultures. 
Significance was determined using Kruskal-Wallis test on ranks compared to control. 
*P<0.05, mean ± SD are shown from n=3. 
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Figure 5.3: Adipocytes increase CD24 in MDA-MB-21 cells with no effect on CD44 
or the Ki67 proliferation marker in any cell line. Representative images of (A) MDA-
MB-231 cells, (B) Hs578t cells and (C) SUM159 cells in the presence or absence of 
adipocytes and conditioned medium co-stained with anti-CD24, anti-CD44, and DAPI 
(left panel), or co-stained with anti-Ki67 and DAPI (right panel) (scale bar=50µm). To 
the right of each image, the average protein expression of 5 images per replicate from 
different fields of view for the BC cells was normalized to DAPI and analyzed relative to 
control cultures. Significance was determined using Kruskal-Wallis test on ranks 
compared to control. *P<0.05, n=3.  
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the co-culture conditions tested (Fig 5.3). 
5.4 The change in morphology or MET of mesenchymal BC cells is specific to 
mature adipocytes 
To determine if I could apply this model to differentiate the effects caused by 
other cell types on the BC cell lines, I examined the effect of undifferentiated pre-
adipocytes co-cultured with BC cell lines, focusing on cell lines that were affected by 
adipocytes. I found that incubation with undifferentiated pre-adipocytes had a partial 
effect on the morphology of the cell lines that was much less dramatic than seen with 
mature adipocytes (Fig 5.4). Similarly, I analyzed EMT markers expression in the BC 
cell lines in the presence of pre-adipocytes and found no effect on any of the cell lines 
(Fig. 5.5). Since MDA-MB-231 were the only cells with changes to CD24, we analyzed 
the effect of pre-adipocytes on this line only for stemness and proliferation makers and 
found that pre-adipocytes caused no significant change in CD24, CD44 or Ki67 
expression (Fig 5.5G, H). 
5.5 LD size is decreased in 3D co-cultures 
 To determine if I was able to analyze the adipocytes, which are located beneath 
the Matrigel layer, I stained adipocyte LD with the fluorescent lipophilic dye BODIPY 
493/503. Using confocal microscopy, I was clearly able to image and analyze both the 
size and number of LDs. I observed that the number of LDs did not significantly change 
in the presence of any of BC cell line (MDA-MB-231: P=0.142, Hs578t: P=0.429, 
SUM159: P=0.999, MCF7: P=0.052) (Fig 5.6B). However, adipocytes displayed an   
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Figure 5.4: Pre-adipocytes have a partial effect on morphology of BC cells. 
Representative images of (A) MDA-MB-231 cells, (B) Hs578t cells and (C) SUM159 
cells grown in the 3D co-culture system in the presence or absence of pre-adipocytes 
(Scale bar=100µm). To the right of each image, the total percentage of structure shapes as 
mean ± SD are shown from 3 biological replicates. Overall significance of the proportion 
of colony shapes between the treatments was determined by 2 analysis, **P<0.01, 
***P<0.001. If significant by 2, differences between the conditions for each shape was 
determined using one-way ANOVA with Tukey HSD post hoc analysis. Different letters 
or symbols represent statistically different groups a,b,cP<0.05 for stellate, 1,2,3P<0.05 for 
grape-like, and α,β,Υ,θP<0.01 for round/mass-like. 
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Figure 5.5: Pre-adipocytes have no effect on MET or on stemness markers of BC 
cells. Representative images of (A) MDA-MB-231 cells, (C) Hs578t cells and (E) 
SUM159 cells cultured with or without pre-adipocytes, and co-stained with anti-
vimentin, anti-ZO-1, and DAPI (left panel), or co-stained with anti-E-cadherin, anti-
Claudin-7 and DAPI (right panel). (B, D, F, H) The average protein expression of 5 
images per replicate from different fields of view for the TNBC cells was normalized to 
DAPI and analyzed relative to control cultures. Significance was determined using 
Kruskal-Wallis test on ranks compared to control. n=3. Representative images of (G) 
MDA-MB-231 cells, grown in 3D culture in the absence or presence of pre-adipocytes, 
and then co-stained with anti-CD24, anti-CD44, and DAPI (left panel), or co-stained with 
anti-Ki67 and DAPI (right panel), (scale bar=50µm).  
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Figure 5.6: Co-culture with BC cells decreases the size but not number of LD 
present in mature adipocytes. (A) Representative images of adipocyte LDs co-stained 
with Bodipy 493/503 and DAPI in the presence and absence of BC cells in the 3D co-
culture system. (scale bar = 100µm), n=3. (B) Number of LDs analyzed from 5 random 
fields of view per replicate shown as mean ± SD. Significant differences were determined 
using Students t-test, n=3. (C) Distributions of areas binned by 50μm2. Significance was 
determined using Kolmogorov-Smirnov test, n=3, **P<0.01, ***P<0.001, mean ± SD are 
shown from n=3. Note: error bars for MCF7 are too small to be visible. 
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altered distribution of LDs sizes in response to co-culture with any of the BC cell lines 
(MDA-MB-231: P<0.0001, Hs578t: P=0.00812, SUM159: P<0.0001, MCF7: P<0.0001) 
(Fig. 5.6C). MDA-MB-231 cells caused a decrease in the number of LD in all bins 100 
m2 or greater. Hs578t cells had a less dramatic effect with a reduction in LD of 250 m2 
or greater. Even MCF7 cells, that were themselves not affected by adipocyte co-culture, 
caused a reduction in LDs 100 m2 and greater. In contrast, we observed an increase in 
the frequency of LDs greater than 150 m2 with SUM159 co-culture. 
5.6 Discussion 
Here, I report on the development and use of a 3D co-culture system to allow the 
evaluation of interactions between two different cell types where both cell types are in 
contact with the ECM. The system I describe does not require custom equipment, 
scaffolding, or other techniques inaccessible to modern cellular biology labs. The system 
has the noted benefit of allowing assessment of epithelial and mesenchymal states that 
are particularly vulnerable to differences in the 2D vs. 3D environment [135].  
I developed this novel 3D co-culture system to enable the analysis of proteins or 
lipid of interest by IF staining and confocal imaging. Here, I focused on analysis of the 
EMT status of BC cell lines using human specific antibodies. I have used adipocytes and 
laminin-rich ECM in this study, however, this method could easily be modified to 
analyse interaction with other types of ECM, stromal cells, or primary cells from mouse 
or human at different stages of cancer progression, and in the presence of drugs or other 
biological activators or inhibitors. Similarly, this 3D co-culture system could be easily 
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modified to allow paraffin embedded IHC staining or electron microscopic imaging 
[333]. It has been shown that BC cells isolated from 3D culture can maintain their 
characteristics for up to 8 weeks, thus, allowing for further assessment of changes to the 
migration and invasion ability induced by co-culture [334, 335].  
It is important to note that the major technical limitation for imaging the 3D co-
cultures is obtaining high resolution images due to the thickness of the sample, which 
limits the ability to obtain well focused images, particularly at higher magnification 
objectives with limited focal length. It is possible that this limitation could be overcome 
by formalin fixed, paraffin embedded - immunofluorescence or immunohistochemistry 
(FFPE-IF/IHC) techniques, which would create thinner physical slices. However, the 
additional processing and need for compatible antibodies adds a different set of caveats. 
[333].  
To demonstrate the utility of this method, we analyzed the effect of adipocytes on 
the 3D morphology of BC cell lines with different proportions of mesenchymal or 
epithelial colonies. Interestingly, and in contrast to a previous report [43], we found that 
adipocytes promoted a partial MET in mesenchymal BC cells, as evidenced by the 
changes to colony morphology and changes in expression of Claudin-7 and E-cadherin in 
MDA-MB-231 and Hs578t cells and vimentin in Hs578t cells. In contrast, SUM159 cells, 
which are more epithelial in 3D-culture, did not show any significant changes to specific 
colony morphologies or EMT marker expression. Surprisingly, MCF7 cells also showed 
no change in their EMT status in the presence of adipocytes even though these changes 
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were seen in Transwell culture studies [43]. This suggests that physical interactions of 
BC cells and adipocytes with the ECM has an essential role in the biology of EMT and 
MET of BC cells. 
Because either physical interactions and secretory factors could be responsible for 
inducing these changes in mesenchymal BC cells, I determined if CM could recapitulate 
the adipocyte-induced effects. I found that CM was sufficient to change the morphology 
of MDA-MB-231 and Hs578t cells to an epithelial-like colony shape but did not induce 
similar MET-like changes in biomarker expression. It must be noted that the CM was 
diluted by 50% at each medium change to ensure replenishment of nutrients for cell 
survival. Thus, the reduced concentration of secretory factors may have caused this 
partial effect. Alternatively, constant exposure of a mediator or the physical presence of 
mature adipocytes may be necessary to surpass a signaling threshold in the BC cells. A 
partial change that was even less dramatic was observed in the presence of pre-adipocytes 
suggesting that the mediator is more abundant or effective when originating from 
adipocytes. 
During EMT in vivo, an increase in BCSC can further enhance invasion and 
migration of the tumor and this change can be suppressed during MET [336]. I found that 
CD24 levels were increased in MDA-MB-231 cells by adipocyte and CM co-culture, but 
not in the other cell lines, with no change in CD44 expression in any cell line. This 
suggests there is no change in the proportion of BCSC in the culture, although future 
investigation is necessary to fully determine this. Since CD24 is an epithelial marker that 
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was found to be increased in metastatic sites [337], the observed increase in CD24 could 
instead be reflective of the observed increase in the epithelial phenotype. Moreover, this 
increase in CD24 might be regulated by suppression of Ras pathway genes by adipocytes. 
The most common sites for secondary tumor formation in TNBC or ER/PR+ 
tumors are bone and lungs [338]. Increased adiposity in the bone marrow has been shown 
to lead to metastasis from ovarian and prostate cancers [113, 339]. However, it is not 
known whether the composition and/or mechanical properties of the ECM at sites of 
metastasis, such as the bone marrow, are similar to that used in the present study. Future 
work will be required to elucidate the precise mechanism(s) contributed by adipocytes to 
BC metastasis at specific sites and the role of the ECM in these processes.  
Differences in LD size suggests that lipid in the adipocytes could be mobilized by 
MDA-MB-231, Hs578t cells, or MCF7, which may provide energy in the form of free 
fatty acids taken up by BC cells to fuel cellular processes. Increased lipolysis by 
adipocytes in the BC microenvironment and increased expression of fatty acid binding 
proteins in ovarian cancer, combined with studies showing high levels of oxidative 
phosphorylation in BC cells, supports this possibility [206, 340]. Alternatively, 
adipocytes can affect BC cells via the increased secretion of leptin, IL-6, TNF, and 
VEGF, as observed in obese patients [104]. In SUM159 cells, there was no decrease in 
LD size which may also explain the lack of change to the phenotype of these cells, 
however it remains to be determined why the MCF7 cell phenotype is unaffected by 
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adipocytes yet LD size is decreased. This suggests the LD might be used only as source 
of energy by these BC cells and might not involved in the phenotypic changes of BC cells 
Breast is a fatty tissue where occurrence of tumor has influential interactions with 
adipocytes [341]. Adipokines such as adiponectin and leptin have opposite effects on BC 
progression. However, leptin secreted by BC cells into microenvironment can bind the 
leptin receptors on the adipocytes activating lipolysis [342, 343]. This could be one of the 
possibilities of decrease of lipid content in adipocytes when co-cultured with BC cells. 
The free fatty acids released might have a reciprocal effect on MET of BC cells. This can 
be explained by blocking leptin and analyzing the effect on BC cells in 3D co-culture. 
Another possibility for the decrease in lipid content could be the presence of fibroblast-
like cells that can be generated by de-differentiation of adipocytes, also called as 
adipocyte derived fibroblasts (ADFs). Cancer associated fibroblasts are a significant part 
of the stromal cell population that contributes to BC progression and metastasis [344]. 
The Wnt/β-catenin pathway is re-activated in ADFs via Wnt3a in the presence of cancer 
cells [345], indicating generation of ADFs. Both de-lipidation and de-differentiation 
increases the free fatty acids, and inflammatory cytokines that leads to aggressive breast 
cancer formation gaining invasive, and migration properties [346]. 
Here, I demonstrate the use of a novel, straightforward, and accessible 3D co-
culture method to show that adipocytes can promote a MET-like change in mesenchymal 
TNBC cells. This work provides more insight into relationship between high adiposity 
and metastasis to bone or other sites with adipocyte abundance. Future work, using this 
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and other models, to identify the mechanism(s) underlying this process may enable 
identification of better therapeutic targets for metastatic BC. 
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Chapter 6. Discussion 
Overall, BC progression and metastasis depends on intrinsic factors such as the 
genetic and epigenetic instability of genes involved in cell growth, proliferation and 
differentiation. It is essential to determine the structure, function, and regulation of these 
genes in order to target and regulate the tumor progression. In addition, BC progression 
and metastasis are further influenced by extrinsic factors such as the stromal cells and 
ECM surrounding cancer cells (Fig 6.1). These extrinsic and intrinsic factors can be 
influenced by other conditions of the patient, such as heredity, aging, or lifestyle issues 
such as obesity, alcohol consumption, or smoking. All of the factors mentioned above can 
interact to enhance BC progression and metastasis. Thus, the goal of this thesis is to 
investigate some aspects of the above-mentioned factors that affect the tumorigenesis, 
progression and metastasis of BC.  
The root cause of tumor initiation is genetic or epigenetic alterations of genes 
involved in cell cycle regulation [347]. Accumulation of mutations in cells decides the 
outcome of tumor progression. Irrespective of the number of mutations, it is mutations in 
driver genes such as RTKs, Ras, PI3K, and ERK, that drives cell proliferation [348]. In 
addition, resistance to cell death, metabolic changes, increased angiogenesis, and invasive 
properties are acquired that further promote tumor progression [349]. Moreover, inter-
dependencies between signaling pathways co-operate with each other in order to achieve 
cancer growth, survival, and progression [321].  
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Figure 6.1: Schematic illustration of the tumor microenvironment showing the 
interaction between the tumor cells and the surrounding ECM and non-cancerous 
cells at secondary site. (A)The tumor consists of a heterogeneous population of cells 
with varied mutation burden between cells. The colored * indicates complexity of cross-
talk between different signaling pathways when cells have multiple mutations. The lipid 
engorged adipocytes are shown interacting with mesenchymal cells, which aid in the 
denaturation of the ECM and subsequent MET of cancer cells at the site of colonization. 
Dashed lines with arrows indicate the interaction within or between cells. Different colors 
of cells within the tumor indicates tumor heterogeneity due to diverse mutations. (B) An 
overview of the extrinsic factors such as adipocytes interacting with BC cells and 
activating signalling cascade such as Ras in the presence of ECM.  
166 
 
Similarly, proteins such as CD24 are downregulated, especially in BCSC in order 
to maintain the stem-like properties of the cells. Here, I have analyzed the structure and 
evolution of the CD24 gene, which plays an important role as a biomarker for BCSCs. 
Analysis of the CD24 gene structure and evolution revealed the importance of 
glycosylation sites that have been conserved over 200 million years. I have shown that 
the CD24 gene structure is dynamic and varies among species. However, the conserved 
glycosylation sites suggests their importance in the CD24 protein function. The role of 
glycosylation in CD24 function among BC cells has not been reported. Comparison of 
glycosylation patterns between neuroblastoma, lymphoblastoma and astrocytoma 
suggests different patterns between these cell types [147]. These conserved regions can 
be considered in the design of potential drugs against the CD24 protein to inhibit or 
stabilize its activity. Moreover, in TNBC patients, differential drug treatment switches the 
CD24+ to CD24low/- phenotype and vice versa, which has been suggested to be a potential 
cause of drug resistance in these patients [350]. Thus, targeting CD24 function may 
reduce drug resistance in TNBC patients. In addition, inhibition of CD24 signaling or 
adhesion might be a potential targeted therapy for the cancers where high CD24 
expression leads to cancer progression [82]. In the future, identifying the glycosylation 
patterns among different BC subtypes could help to explain the dynamic role of CD24 
signaling between these cancer cells.  
Understanding the regulation of CD24 can contribute to understanding the 
regulation of BCSC and TNBC progression. Thus, I targeted multiple downstream 
proteins of Ras to understand the regulation of CD24 protein expression by the Ras 
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pathway. However, I found that complex cross-talk downstream of Ras triggers multiple 
pathways to downregulate CD24 at promoter, mRNA, and protein levels. This suggests 
that it is important for BC cells to downregulate CD24 surface protein expression, which 
might involve in inhibition of signaling that inhibits tumorigenesis and proliferation. 
Moreover, I have shown that Ras downregulates CD24 mRNA and protein independently 
via the Raf/MEK or the PI3K/Akt pathway. Identifying the regulatory pathways of CD24 
that regulate the BCSC phenotype may allow for the identification of strategies to reduce 
drug resistance and progression in TNBC patients. BCSC can be identified by the 
absence of CD24 on cell surface, this suppression might be regulated by oncogenic Ras 
pathway. Targeting the proteins involved in protein trafficking downstream of Ras to 
promote CD24 expression on cell surface or inhibition of microRNA to increase the 
stability of CD24 mRNA or identifying the TF that repress CD24 promoter regions to 
increase CD24 transcription in RasV12 cells and BC cells are the potential future 
strategies to understand the downregulation of CD24 by oncogenic Ras at multiple levels.  
In addition to the internal regulation of cancer cells, driver mutations can trigger 
activation of signaling networks to allow interactions with non-cancerous cells and the 
ECM in the microenvironment that is favorable for tumor progression. The breast TME 
consists of a heterogenic population of cells, including proliferating host cells, cancer 
stem cells, and stromal cells such as immune cells, endothelial cells, and adipocytes. 
Autocrine and paracrine signaling among these cells via growth factors and chemokines 
causes changes in metabolism, oxidative stress, and hypoxia that contribute to cancer cell 
growth, dissemination, and metastasis (Fig 6.1). Therefore, I have studied the 
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contribution of the ECM and adipocytes to BC progression through the use of a newly 
developed in vitro 3D co-culture system.  
The ECM is the soul of the microenvironment, providing biophysical and 
mechanical support to the tumor. In vitro 3D cell culture studies have revealed the 
invasive properties and metastatic efficiencies of cancer cells in ECM [351]. Secretion of 
MMPs by stromal cells changes the dynamics of the microenvironment to allow 
morphological dissemination of cancer cells away from the solid tumor. In addition, 
adipocytes can also secrete ECM proteins, especially collagen type I and fibronectin, that 
stiffens the breast tumor microenvironment, leading to hypoxic or acidic conditions that 
allow cancer cells to survive over normal cells [352]. Moreover, in addition to systemic 
changes caused by obesity, the effect of adipocytes on cancer progression is worsened, 
resulting in poor disease outcome in cancer patients. Adiposity causes increased 
inflammatory cytokines, free fatty acids, and IGF1, contributing to changes in metabolic 
activity to allow the cancer cells to survive. There is increased drug resistance in obese 
patients due to the increased stiffness of the ECM, which further changes the dynamics of 
the vasculature that can restrict the delivery of chemotherapy. Here, I have developed an 
in vitro 3D co-culture system that can potentially aid in finding new therapeutic targets 
present in microenvironment that enhance BC progression. Therapeutic targeting of the 
tumor microenvironment in any condition, in addition to targeting the specific gene 
expression, will have more profound effect when compared to general chemotherapy. In 
the future, identifying the soluble mediator that is involved in this partial MET can 
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provide a new strategy to treat metastasis in BC patients. This effect of soluble mediator 
on MET of BC cells can be validated using human adipocytes.  
Overall, for the very first time I have identified the presence of CD24 in the tree 
of evolution since the divergence from reptiles. Moreover, CD24 functional regions are 
evolutionarily conserved. I also found that oncogenic Ras downregulates both CD24 
mRNA and protein expression by multiple mechanisms. Downregulation of CD24 
surface protein can be relieved by supressing Raf activity only when Ras is mutated and 
this can not be achieved in BC cells where additional mutations are present (Fig 6.1B). 
This suggests that inhibition of Raf is not sufficient to increases CD24+ population in BC 
cells. Finally, I developed a novel 3D co-culture system, where two different cell lines 
can be studied in the presence of ECM. Moreover, I found that adipocytes promote partial 
MET, suggesting its role in colonization of BC cells at secondary site during micro or 
macro-metastasis. Cancer metastasis is the leading cause for death from cancer. Tumor 
heterogeneity, the presence of cancer stem cells, and TME, all contribute to resistance to 
therapy. To overcome the drug resistance, heterogeneity, and aggressiveness of the 
TNBC progression, targeting intrinsic factors is not sufficient. In order to achieve 
effective drug treatment, it is important to consider the extrinsic factors present in the 
microenvironment that contribute to TNBC progression. Over the last decade, 
personalized medicine, where combination drugs targeting the genetic changes specific to 
the patient, has been found to improve treatment response in patients with cancer [353]. 
Overall, considering both intrinsic and extrinsic factors in combination drug treatment 
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that can target different aspects of the tumor such as microenvironment and intrinsic 
factors including function and regulation of genes, is the future of the TNBC treatment.   
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Appendix I:  
Accession numbers for nucleotide sequences for 106 CD24 genes from 56 different 
species 
Refseq accession numbers 
NM_001291737.1_Human_v2 
NM_001291738.1_Human_v3 
NM_009846.2_House mouse 
NM_012752.3_Norway rat 
XM_002690126.3_Cow 
XM_010968193.1_Bactrian camel 
XM_010621816.1_Damaraland mole rat 
XM_010707543.1_Turkey 
XM_010573395.1_Bald eagle 
XM_009093196.1_Common canary 
XM_008120756.1_Green anole 
XM_008007449.1_Green monkey_v1 
XM_008576828.1_Lemur 
XM_008007450.1_Green monkey_v2 
XM_007940836.1_Ant bear 
XM_006982756.1_Prairie deer mouse 
XM_003940810.2_Black capped-squirrel monkey 
XM_003902737.2_Olive baboon 
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NM_013230.3_Human_v1 
XM_003496974.2_Chinese hamster 
XM_009242120.1_Sumatran orangutan_v3 
XM_008994848.1_Marmoset_v1 
XM_008994849.1_Marmoset_v2 
XM_008994850.1_Marmoset_v3 
ENSVPAT00000011368_Alpaca 
ENSCAFT00000011592_Dog 
ENSLAFT00000007742_Elephant 
ENSMPUT00000009749_Ferret 
ENSNLET00000023931_Gibbon 
ENSGGOT00000004639_Gorilla 
ENSCPOT00000006426_Guinea pig 
ENSECAT00000003157_Horse 
ENSETET00000010513_Lesser Hedgehog 
ENSMMUT00000022072_Rhesus monkey 
ENSPVAT00000004436_Mega bat 
ENSSSCT00000036499_Pig 
ENSOCUT00000008424_Rabbit 
ENSOART00000012053_Sheep 
ENSCHOT00000001451_Sloth 
XM_004478726.1_Armadillo_L1 
XM_004481863.1_Armadillo_L2 
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XM_005898197.1_Wild yak_L1 
XM_003919300.2_Olive baboon_L1 
XM_008847580.1_Blind mole rat_L1 
XM_005377835.1_Chinchilla 
XM_004638116.1_Degu1 
XM_004627458.1_Degu2 
XM_004641652.1_Degu3 
XM_004627999.1_Degu4 
XM_004637468.1_Degu5 
XM_004623618.1_Degu6 
XM_006987801.1_Prairie deer mouse_L1 
XM_004328888.1_Commonn bottle nosed dolphin_L1 
XM_004313735.1_Commonn bottle nosed dolphin_L2 
XM_004315594.1_Commonn bottle nosed dolphin_L3 
XM_005086648.1_Golden hamster 
XM_003784394.1_Galagos_L1 
XM_003794749.1_Galagos_L2 
XM_003266872.2_Gibbon_L1 
XM_003274235.2_Gibbon_L2 
XM_004837180.1_Naked mole rat_L1 
XM_004836422.1_Naked mole rat_L2 
XM_004855435.1_Naked mole rat_L3 
XM_004874111.1_Naked mole rat_L4 
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XM_004854271.1_Naked mole rat_L5 
XM_004904554.1_Naked mole rat_L6 
XM_004846605.1_Naked mole rat_L7 
XM_004711196.1_Lesser hedgehog_L1 
XM_004713801.1_Lesser hedgehog_L2 
XM_004703339.1_Lesser hedgehog_L3 
XM_004663354.1_Lesser egyptian Jerboa_L1 
XM_004649227.1_Lesser egyptian Jerboa_L2 
XM_004580347.1_American pika_L1 
XM_005363586.1_Prairie vole_L1 
XM_004422395.1_White rhinoceros_L1 
XM_004436349.1_White rhinoceros_L2 
XM_004422175.1_White rhinoceros_L3 
XM_010369128.1_Golden snub nosed monkey_L1 
XM_005339711.1_Thirteen-lined squirrel monkey_L1 
XM_005335884.1_Thirteen-lined squirrel monkey_L3 
XM_006159537.1_Chinese tree shrew_L1 
XM_006141239.1_Chinese tree shrew_L4 
XM_006141355.1_Chinese tree shrew_L5 
XM_006146472.1_Chinese tree shrew_L6 
XM_006143224.1_Chinese tree shrew_L7 
XM_006142132.1_Chinese tree shrew_L10 
XM_006168651.1_Chinese tree shrew_L12 
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XM_006165654.1_Chinese tree shrew_L13 
XM_006168455.1_Chinese tree shrew_L15 
XM_006165703.1_Chinese tree shrew_L16 
XM_004411181.1_Pacific walrus_L1 
XM_004412424.1_Pacific walrus_L2 
XM_004391983.1_Pacific walrus_L3 
XM_004407337.1_Pacific walrus_L4 
XM_004406937.1_Pacific walrus_L5 
XM_004397896.1_Pacific walrus_L6 
XM_004065199.1_Western gorilla_L1 
XM_004056236.1_Western gorilla_L2 
XM_004278400.1_Killer whale_L1 
XM_004283237.1_Killer whale_L2 
XM_004278507.1_Killer whale_L3 
XM_004271919.1_Killer whale_L4 
XM_004274529.1_Killer whale_L5 
XM_004284471.1_Killer whale_L6 
XM_004264763.1_Killer whale_L7 
XM_004281528.1_Killer whale_L8 
XM_006181997.1_Wild camel_L1 
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Appendix II: 
 R-script for one way ANOVA analysis 
setwd() #select the folder as working directory 
getwd() #confirm the folder 
vectorname<-read.csv("filename.csv", header=T) #reads the contents of the file 
summary(vectorname) #lays out the summary of the file contents 
colnames(vectorname) #lays out the column names in the file 
ShapeAOV<-
aov(vectorname$Colname1(parameter1)~vectorname$colname2(parameter2)) #call 1-
way anova, order is important, vectorname$Colname  
summary(ShapeAOV) #results of anova, if significant proceed with Tukey    
TukeyHSD(ShapeAOV) #post-hoc test  
 
